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Congenital Hyperinsulinism of Infancy (CHI) is a group of rare inherited disorders 
characterized by persistent hypoglycaemia due to inappropriate elevated secretion of insulin 
from the pancreatic beta cells. CHI can be caused by abnormalities in at least 10 genes. One of 
them, HADH, encodes the mitochondrial enzyme SCHAD, which has two functions: it catalyses 
the third step in the oxidation of fatty acids, and it has been reported to negatively regulate the 
enzyme glutamate dehydrogenase (GDH). Inactivating mutations in HADH lead to a loss of the 
inhibitory protein interaction of SCHAD, which then cause increased insulin secretion due to 
overactive GDH.  
 
We here aimed to understand the functional impact of rare SCHAD variants present in human 
populations. We have explored the effect of four pathogenic SCHAD variants with regard to 
the level of expression, subcellular localization and enzymatic activity. Two of the variants 
(G34R and I184F) showed protein instability and had clearly reduced level of protein 
expression in HEK293 cells. The mRNA levels appeared normal, which indicated that the cause 
of instability lies downstream of the transcription. The two other variants (K136E and M188V) 
had normal protein expression levels in HEK293 cells, but a severely reduced enzymatic 
activity compared to the wild type protein. The four SCHAD mutations did not affect the 
mitochondrial localization of the protein. In addition to the four pathogenic variants, protein 
stability of 11 other rare SCHAD variants was tested in HEK293 cells by the use of the protein 
synthesis inhibitor cycloheximide. Four additional variants were found to be unstable (I33M, 
H170R, P258 and G303S). The effect of the different SCHAD variants on GDH interaction was 
evaluated by co-immunoprecipitation. Protein:protein interaction could be detected for the 
SCHAD wild type protein, whereas several of the other variants seemed to have reduced or lost 
binding to GDH. The data gathered throughout the study were in combination with other 
relevant information used to reclassify the pathogenicity of a total of 16 rare SCHAD variants 
present in human populations. Taken together, our results illustrate the extensive work 
necessary for evaluating the functional impact of rare variants that are identified in high-






1. Introduction  
 
1.1 The endocrine pancreas 
The pancreas is a digestive gland located posteriorly to the stomach, between the duodenum 
and the spleen (Figure 1.1A) [1]. The organ can be divided into two functional compartments: 
the endocrine and the exocrine pancreas. The exocrine pancreas constitutes the major part of 
the organ and contains acinar and ductal cells producing digestion enzymes and bicarbonate, 
respectively, which are secreted into the duodenum as pancreatic juice. The endocrine pancreas 
regulates energy metabolism by producing the hormones insulin, glucagon, and somatostatin 
[2]. The project described in this thesis concerns the endocrine elements, which will therefore 
be the focus of the introduction.  
 
1.1.1 The islets of Langerhans  
The endocrine pancreas consists of approximately 1 million cell clusters called the islets of 
Langerhans (Figure 1.1B). These clusters constitute 1-2% of the pancreas [2]. The islets contain 
four major cell types: beta (54%), alpha (35%), delta (11%) and gamma/pancreatic polypeptide 
cells (a few percent) [3]. The different endocrine cell types produce hormones that mainly serve 
to coordinate responses to maintain glucose homeostasis. The beta cells produce insulin, the 
alpha cells produce glucagon, the delta cells secrete somatostatin, and the polypeptide cells 
secrete vasoactive intestinal peptide [2]. The islets are intimately connected to the vasculature, 




Figure 1.1 – Structure and function of the human pancreas. A) The pancreas (yellow) is located in the abdomen, with the 
duodenum on the right side and the spleen on the left. Other surrounding organs and major vessels are also shown. Figure from 
[5]. B) The islets of Langerhans are scattered throughout the pancreas. The endocrine cells produce glucose-regulating 
hormones that are released into the blood stream. Figure adapted from [6].  
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1.1.2 Regulation of insulin secretion 
Insulin secreted from the beta cells is the main regulator of blood glucose level, ensuring that it 
is in balance with the body’s feeding state. During food intake, i.e. when blood sugar rises, the 
beta cells sense this change and secrete insulin into the blood stream in corresponding amounts. 
This enables striated muscle cells and adipocytes to absorb the glucose and use it as energy. 
Excess glucose is stored in the liver and muscles as glycogen  through the process known as 
glycogenesis, and can be released at times of energy shortage [2]. Insulin also stimulates storage 
of excess fuel as fat in adipose tissue [7]. 
 
Glucagon secreted from the alpha cells has the opposite effect of insulin on the blood glucose 
level, as shown in Figure 1.2. Thus, whereas insulin lowers the level of blood glucose, glucagon 
increases it [8]. These hormones thereby work together to maintain appropriate blood glucose 
levels, which normally are in the range of 3.5-5.5 mmol/L in humans [9]. Glucagon signalling 
results in the net output of glucose from the liver through glycogen breakdown, gluconeogenesis 
(conversion of protein to glucose) and inactivation of glycogen synthesis. In addition, it 





Figure 1.2 – Opposing effects of insulin and glucagon in the regulation of blood glucose. Insulin and glucagon work 
together to maintain blood glucose levels within a normal range. When blood glucose is high, insulin is released from the 
pancreatic beta cells. Insulin stimulates the uptake of glucose into cells in a variety of tissues, here exemplified by adipose 
tissue. When blood glucose is low, glucagon is released from the pancreatic alpha cells. Glucagon serves to raise the glucose 




Insulin is also secreted from the beta cells in response to additional nutrients such as other 
monosaccharides, amino acids and free fatty acids. However, the response to glucose is the 
strongest. Several hormones like melatonin, estrogen, leptin, growth hormone and glucagon 
like peptide-1 affect the regulation of insulin secretion [4]. 
 
Insulin is stored in secretory granules within the beta cells, and is released through the fusion 
of these granules with the plasma membrane [2]. The main steps in the pathway of insulin 
secretion are shown in Figure 1.3. After glucose has entered the beta cells, it is converted to 
pyruvate through glycolysis. Pyruvate is then metabolized to acetyl-CoA, which is oxidized in 
the mitochondria by the tricarboxylic acid cycle (TCA cycle) to produce ATP [4]. The rise in 
ATP concentration initiates the closure of the KATP channels in the beta cell plasma membrane, 
reducing the efflux of potassium (K+), which in turn causes the depolarization of the cell 
membrane. The depolarization triggers opening of voltage-gated calcium (Ca2+) channels, and 
leads to an influx of Ca2+ into the cell [11]. The increase in intracellular Ca2+ concentration is 
the primary insulin secretory signal [4] that initiates the exocytosis of insulin from the secretory 
granules [11]. 
 
                        
Figure 1.3 – Main steps in the pathway of insulin secretion. Glucose metabolism in the pancreatic beta cells results in an 
increased ATP:ADP ratio, which leads to closure of ATP-gated K+ channels. Depolarization of the beta cell membrane leads 
to opening of voltage-gated Ca2+ channels. Increased intracellular Ca2+ concentration initiates exocytosis of insulin from 





Insulin is required to maintain normal energy metabolism [4]. Defects in the secretion and/or 
action of insulin can lead to diabetes, which is the most common disease that involves the 
pancreas. Diabetes is a group of metabolic disorders where the hallmark is chronic 
hyperglycaemia, i.e. a fasting blood glucose level above 7 mmol/L [2]. 
 
According to the American Diabetes Association (ADA), diabetes can be classified into four 
main categories: type 1 diabetes, type 2 diabetes, gestational diabetes mellitus, and specific 
types of diabetes due to other causes, like monogenic diabetes syndromes [13]. 
 
Type 1 diabetes is caused by cell-mediated autoimmune destruction of the pancreatic beta cells. 
This form accounts for 5-10% of all diabetes cases. As the disease proceeds, at a rate according 
to the rate of beta cell destruction, the patients will have little or no remaining insulin secretion, 
and they therefore become completely dependent on treatment with insulin for survival. Type 
1 diabetes typically has a juvenile onset, but can also occur in adults. The disease is defined by 
the presence of autoimmune markers [13]. 
 
Type 2 diabetes is the most prevalent form of diabetes and accounts for around 90% of all cases. 
Although the disease is commonly known as “lifestyle diabetes”, it also has a strong genetic 
component. Type 2 diabetes typically has an adult onset, and the risk of developing the disease 
increases with obesity and lack of physical activity. The disease is defined by a combination of 
relative insulin deficiency (inadequate response) and a peripheral insulin resistance [13].  A loss 
of beta cells mass and function, in addition to dysfunction in insulin secretion, makes the beta 
cells unable to secrete enough insulin to compensate for the decrease in insulin sensitivity in 
the patients. [4] Since there is no autoimmune destruction of the beta cells, many of the patients 
can manage their disease by interventions in diet and lifestyle. Nevertheless, oral medications 
are often needed and some patients eventually become insulin-dependent [13].  
 
Gestational diabetes mellitus (GDM) can appear in women in their second or third trimester of 
pregnancy. The diagnosis is given if there was no diabetes before the pregnancy. Normal 
glucose level in usually restored when the baby is born. However, GDM increases the risk of 




Monogenic diabetes is a group of diseases caused by around 20 single-gene defects that affect 
the development of the pancreas or the physiology of the beta cell [14]. Monogenic diabetes 
syndromes include neonatal diabetes and maturity-onset diabetes of the young (MODY). The 
monogenic forms account for somewhere between 1% and 5% of all diabetes cases. Neonatal 
diabetes appears before the age of 6 months, and can be transient or permanent. Overexpression 
of genes on chromosome 6p24 leads to the transient type, while autosomal dominant mutations 
in the two genes that encode the subunits of the KATP channels in the beta cells (KNCJ11 and 
ABCC8) result in permanent neonatal diabetes. MODY is characterized by impaired insulin 
secretion, with minimal or no defects in insulin action. The disease is inherited in an autosomal 
dominant pattern most commonly caused by abnormalities in the genes GCK, HNF1A and 
HNF4A [13].  
 
Other causes of diabetes included in the ADA classification are diseases of the exocrine 
pancreas (e.g. cystic fibrosis- or pancreatitis-related diabetes) and drug- or chemical-induced 




1.2 Congenital hyperinsulinism of infancy 
1.2.1 Definition and phenotype 
Congenital hyperinsulinism of infancy (CHI) is a group of inherited disorders characterized by 
hypoglycaemia and inappropriately elevated secretion of insulin [12]. Thus, insulin is secreted 
from the beta cells even though the blood glucose level is low, and CHI can be considered as 
the opposite condition of diabetes. The unregulated secretion of insulin leads to inhibition of 
gluconeogenesis, fatty acid oxidation and ketogenesis. CHI therefore prevents the brain from 
all sources of fuel [15]. Some affected children have high birth weight due to high insulin 
secretion also in utero.  
 
CHI has an incidence of around 1 in 50 000 births, but it is more frequent (up to 1:2500) in 





1.2.2 Molecular causes 
During the last two decades, abnormalities in at least 10 genes have been described to cause 
CHI, all of which are involved in the regulation of insulin secretion [11]. The gene defects can 
be divided into three main groups. The first is designated channelopathies and arise from 
mutations in genes that encode the two subunits of the KATP channels in the beta cells (ABCC8 
and KCNJ11, both located on chromosome 11) [17, 18]. The second group consists of 
metabolopathies, in which the underlying defect is dysregulated metabolic pathways. These are 
much rarer than the channelopathies [19]. The third group includes genes that encode 
transcription factors.   
 
1.2.2.1 Channelopathies causing CHI  
Inactivating mutations in the ion channel genes ABCC8 and KCNJ11 cause the most severe 
forms of CHI. [17, 18]. ABCC8 encodes the sulfonylurea receptor 1 protein (SUR1), while 
KCNJ11 encodes the inward rectifier K+ channel Kir6.2. The KATP channel of the pancreatic 
beta cell consists of eight subunits, four of each of these two proteins, as shown in Figure 1.4A. 
The main role of SUR1 is to regulate the activity of Kir6.2, which is the pore-forming unit that 
enables the flow of K+ ions. The KATP channels sense the level of ATP in the beta cells and are 
inhibited by high levels. Inactivating mutations that cause defective KATP channels will lead to 
a persistent depolarization of the beta cell membrane, opening of voltage gated calcium 
channels, and hence unregulated insulin secretion (Chapter 1.1.2) [11]. Mutations in the ABCC8 
gene are by far the most common cause of CHI [20, 21]. 
 
Histologically, CHI caused by KATP mutations can be divided into two major forms: focal and 
diffuse. In focal CHI (30-40% of all channel CHI cases) only localized parts of the pancreas are 
affected by the disease, and the surrounding parenchyma cells appear normal. Focal CHI is 
result of a paternally inherited mutation in the KATP channels, followed by a somatic loss of 
heterozygosity affecting the normal maternal allele. In diffuse CHI (60-70% of all channel CHI 




Figure 1.4 – Molecular causes of CHI. A) The ATP-gated K+ channels of the pancreatic beta cell consist of four SUR1 and 




1.2.2.2 Metabolopathies causing CHI  
The known CHI genes encoding metabolic enzymes are GLUD1, GCK, SLC16A1, UCP2, HK1 
and HADH. GLUD1 encodes the metabolic enzyme glutamate dehydrogenase (GDH). GDH 
catalyses a reversible reaction that converts glutamate to α-ketoglutarate, which enters the TCA 
cycle resulting in production of ATP in the beta cell. Activating mutations in GLUD1 will 
therefore result in too much ATP and enhanced insulin secretion [11]. This is the second most 
common form of CHI after the channelopathies. It has a dominant inheritance pattern [22, 23]. 
 
GCK encodes the enzyme glucokinase, which is responsible for converting glucose to glucose-
6-phosphate in the first activating step of the glycolytic pathway. Dominant activating 
mutations in GCK will increase the concentration of activated glucose inside the cell, and 
thereby lower the glucose threshold for release of insulin [11, 24]. This is the third most 
common cause of CHI [25].  
 
HK1 encodes the enzyme hexokinase 1, which similarity to glucokinase catalyses the first step 
in the metabolism of glucose. HK1 expression is normally silenced in the beta cells, but 
activating mutations can lead to inappropriate activation of hexokinase in the islets. This will 




SLC16A1 encodes the monocarboxylate transporter 1 (MCT1), a protein responsible for 
regulating the transport of lactate and pyruvate into the beta cells. Under normal conditions the 
transporter is not expressed in the beta cells to prevent hypoglycaemia during heavy exercise, 
but gain-of-function mutations can enable its expression also in these cells. Increased transport 
of pyruvate results in higher ATP levels, which again inhibit the KATP channels and lead to CHI 
[11]. Specific for this form of CHI is that the patients experience exercise-induced 
hypoglycaemia [27]. During anaerobic exercise, the produced lactate will enter the TCA cycle 
together with pyruvate and result in production of ATP [11]. 
 
UCP2 encodes the mitochondrial uncoupling protein 2 (UCP2). UCP2 functions by mediating 
leakage of protons across the inner mitochondrial membrane, thereby inhibiting the generation 
of ATP and subsequently the secretion of insulin [9]. Loss-of-function mutations release this 
uncoupling and may enhance the oxidation of glucose in the beta cell to a degree sufficiently 
for CHI to develop [11, 28].  
 
The final CHI gene that encodes a metabolic enzyme, HADH, will be the focus of Chapter 1.3.   
 
1.2.2.3 Defects in genes encoding transcription factors that cause CHI  
This third group of CHI genes encode the transcription factors hepatocyte nuclear factor 1 alpha 
(HNF1A) and hepatocyte nuclear factor 4 alpha (HNF4A). Mutations in these genes can lead to 
a transient form of CHI with a highly heterogeneous phenotype. HNF1A encodes a transcription 
factor that enhances the expression of several pancreatic genes. Heterozygous loss-of-function 
mutations can lead to CHI with a relatively mild phenotype. Some of the patients later progress 
to develop MODY3 diabetes [11]. HNF4A regulates several genes involved in insulin secretion. 
Dominant inactivating mutations in HNF4A may lead to a more severe form of CHI. Patients 
with this form of CHI will eventually develop MODY1 diabetes [11]. Since mutations in 
HNF1A and HNF4A are associated with the development of diabetes later in life, an accurate 
molecular diagnosis is important to ensure appropriate surveillance. The molecular causes of 







Table 1.1 – Molecular causes of CHI. D = autosomal dominant inheritance, R = autosomal recessive inheritance, IM = 












Channelopathies ABCC8 Sulfonylurea receptor 1 (SUR1) D/R IM 
KCNJ11 Inward rectifier K+ channel Kir6.2 D/R IM 
Metabolopathies GLUD1 Glutamate dehydrogenase (GDH) D AM 
GCK Glucokinase (GCK) D AM 
HADH Short chain L-3-hydroxyaxyl-CoA 
dehydrogenase (SCHAD) 
R IM 
SLC16A1 Monocarboxylate transporter 1 (MCT1) D AM 
UCP2 Mitochondrial uncoupling protein 2 (UCP2) D AM 
HK1 Hexokinase (HK1) D AM 
Transcription 
factor genes 
HNF1A Hepatocyte nuclear factor 1 alpha (HNF1A) D IM 
HNF4A Hepatocyte nuclear factor 4 alpha (HNF4A) D IM 
 
 
1.2.3 Treatments of CHI 
In most cases, the phenotype of CHI becomes apparent within a few days or weeks after birth. 
If not treated, the unregulated insulin secretion can lead to severe hypoglycaemia. This is a 
critical condition as the brain is especially vulnerable during the first years of development, and 
glucose is the main fuel of the brain. A delay in diagnosis and lack of treatment in the neonatal 
period can therefore cause permanent brain damage or, in worst-case scenarios, even death [9]. 
Genetic mutation testing/screening of children with hypoglycaemia, when CHI is suspected, is 
important for early diagnosis, determination of the cause of disease, and implementation of the 
optimal treatment. This is vital to ensure the best possible outcome for the patient [29]. 
 
Diazoxide is the most common medical treatment in CHI and is usually the first treatment tested 
when a child is diagnosed with the disease. Diazoxide is a KATP channel agonist that stimulates 
the channels to remain open and hence suppresses the release of insulin [29]. However, 
diazoxide will only be effective in cases where there is no defect in the KATP channels. If the 
channels are affect, octreotide is a treatment option that inhibits the release of insulin 




Patients with KATP mutations are often unresponsive to drug treatment because the KATP 
channels are either defective or absent [11]. Regulated food intake and tube feeding can be 
helpful in some cases. If medications do not give the appropriate response, a partial or subtotal 
surgical removal of the pancreas may be needed [12]. Subtotal pancreatectomy will in most 
cases eventually result in diabetes and exocrine insufficiency, and should therefore be avoided 
if not absolutely necessary [11]. 
 
In the case of KATP mutations, it is particularly important to distinguish between focal and 
diffuse cases. This is because removal of a localized lesion can cure the patient [30]. 
Identification of focal lesions are now done by 18F-fluoro-L-dihydroxyphenylalanine (18F-
DOPA) PET scans [29]. 
 
 
1.3 SCHAD deficiency as cause of CHI 
1.3.1 Discovery and phenotype  
Short-chain L-3-hydroxyacyl-CoA dehydrogenase (SCHAD) deficiency is a rare cause of CHI, 
and was first discovered by Clayton et al. in 2001 [31] when examinations of an infant with 
episodes of hypoglycaemia showed elevated blood level of 3-hydroxybutyryl-carnitine (a fatty 
acid metabolite). This led to activity measurements of fatty acid oxidation (FAO) enzymes, of 
which the enzyme SCHAD showed a clearly reduced activity. Sequencing of the SCHAD 
encoding gene (HADH) discovered an inactivating mutation [31]. This was the first time an 
enzyme from the FAO pathway was directly connected to CHI. At the time, the role of the 
observed HADH mutation as the cause of CHI was regarded with some scepticism, and it was 
speculated that there was an additional unidentified mutation that explained the disease.  
 
In 2004, Molven et al. finally established SCHAD deficiency as a cause of CHI [32]. A whole-
genome scan with microsatellite markers of a consanguineous family with four cases of CHI 
pinpointed the mutated gene to chromosome 4, and a disrupted splice site in exon 5 of HADH 
was then revealed in affected subjects. Like the patient reported by Clayton et. al, these 
individuals also showed reduced SCHAD activity, and increased blood 3-hydroxybutyryl-
carnitine concentration [32]. In 2016, Molven et al. transplanted islets from global SCHAD KO 
(knock out) mice into mice with induced diabetes, and showed that hypoglycaemia in SCHAD-




Abnormal levels of fatty acid metabolites, namely increased concentration of 3-hydroxybuturyl 
in blood and 3-hydroxyglutaric acid in urine, are characteristics of SCHAD-deficiency [32, 33]. 
In contrast to many other CHI forms, affected children have normal birth weights, and even 
though SCHAD participates in the degradation of fatty acids, no phenotypic features of fatty 
acid oxidation disorders (hepatic dysfunction, cardiomyopathy or skeletal muscle affection) are 
seen [34].  
 
 
1.3.2 The HADH gene 
The gene coding for the SCHAD protein is located on chromosome 4q22-26 (Figure 1.5A) and 
is known as HADH (hydroxyacyl-CoA dehydrogenase). In databases such as UniProt 
(https://www.uniprot.org), NCBI (https://www.ncbi.nlm.nih.gov) and Ensembl (https:// 
www.ensembl.org), there are at least three protein coding transcript variants reported, which 
are produced by alternative splicing. The encoded isoforms have a length of 331, 318 and 314 
amino acids (aa) (Figure 1.5B). The 314 aa isoform (reference sequence NM_005318.43) used 
in this study is the most well-characterized one and considered as the main form. The variant 
encoding this isoform is lacking the exon 7, as illustrated in Figure 1.6. There is little or no 




Figure 1.5 – Location, structure and transcript variants of the HADH gene. A) HADH is located on chromosome 4q22-
26, as shown by the red box. B) Comparison of three protein coding transcript variants of HADH. The encoded isoforms have 
a length of 331 (HADH-209), 318 (HADH-210) and 314 aa (HADH-201). The bars represent the exons and the lines are the 
intronic regions. The image was obtained from the Ensembl browser (https://www.ensembl.org/Homo_sapiens 





1.3.3 The SCHAD protein structure 
The SCHAD protein has a 314 aa with the first 12 aa constituting a mitochondrial import signal. 
This signal directs the protein to the mitochondrial compartment, and is cleaved while the 
protein is translocated. The mature SCHAD protein has two domains: a NAD+-binding, and a 
C-terminal dimerization domain (Figure 1.6).  It has been shown that SCHAD forms 
homodimers, which are essential for its stability. The dimerization of two SCHAD molecules 





Figure 1.6 – Schematic organization of the domains of the SCHAD protein and coding exons. SCHAD has a total length 
of 314 amino acid residues. It has an N-terminal mitochondrial signal peptide (MIS), a NAD+-binding domain and a C-terminal 
dimerization domain. The protein is encoded by 8 exons from the HADH gene, lacking exon number 7. Figure made based on 
gene ID 3033 and reference sequence NM_005327.4 in the NCBI database (https://www.ncbi.nlm.nih.gov/nuccore/ 




The N-terminal SCHAD domain consists of a β-α-β fold (eight stranded β-sheet flanked by α-
helices), while the C-terminal domain is primarily α-helical (Figure 1.7) [35, 36]. The two 
domains are connected by a short highly conserved linker region [35]. In the context of the 
catalytic activity of SCHAD in the FAO pathway, the binding of the substrate takes place at the 
interface of the two domains. The active site contains a highly conserved histidine-glutamate 
pair [35], where the catalytic mechanism includes deprotonation of the substrate by the histidine 
residue, which works as a catalytic base. Then, the glutamate residue neutralizes the positive 
charge of the histidine. Presence of the NAD+ cofactor greatly increases the affinity of the active 





Figure 1.7 – Tri-dimensional model of SCHAD. SCHAD consists of mitochondrial signal peptide (yellow), a NAD+ binding 
N-terminal domain (green) and a C-terminal dimerization domain (blue). The N-terminal domain contains a β-α-β-fold, while 
the C-terminal domain is primarily α-helical. The FAO substrate binds at the interface of the two domains. The image was 




1.3.4 SCHAD functions 
As already mentioned, SCHAD is considered to have two different roles: one in the FAO 
pathway and the second in the regulation of insulin secretion (Chapter 1.3.1). A number of 
studies suggest that these two SCHAD functions are independent off each other  [33, 38] [34]. 
For instance, even though SCHAD is ubiquitously expressed in all cells, unlike the other FAO 
enzymes it has very high expression levels in the beta cells compared to the surrounding tissue 
[39]. The function of SCHAD in the FAO pathway will be briefly described below, while its 
role in insulin regulation will be discussed in Chapter 1.3.5.  
 
Fatty acids are a source of energy during fasting, in addition to being a main source of energy 
for the heart, skeletal muscle and kidneys [40]. After being activated to acyl-coenzyme A (Co-
A) in the cytosol, fatty acids are imported from the cytosol to the mitochondrial matrix by the 
carnitine shuttle where the FAO takes place. FAO is a cyclic process consisting of four steps 
(Figure 1.8), where each cycle releases two carbon atoms in the form of acetyl-CoA from the 
fatty acid that is degraded [40]. SCHAD catalyses the third of these steps, which is a 
dehydrogenation of 3-hydroxyacyl-CoA esters to 3-ketoacyl-CoA, coupled to the reduction of 
NAD+ to NADH [41]. In each step of the cycle there are several overlapping chain length-
specific enzymes; in the third step SCHAD is responsible for degrading fatty acids of short and 




Figure 1.8 – SCHAD function in the FAO pathway. SCHAD catalyses the third of four enzymatic steps in the FAO, namely 




1.3.5 Mechanism of insulin dysregulation 
It has been proposed that under normal conditions, SCHAD regulates the secretion of insulin 
through its interaction with GDH [38, 42]. GDH is, as described in Chapter 1.2.2.2, a 
mitochondrial enzyme that links the TCA cycle to the dehydrogenation of the amino acid 
glutamate, and thereby links carbohydrate and protein metabolism [43]. When bound to GDH, 
SCHAD inhibits GDH activity (Figure 1.9), which eventually will result in the down-regulation 
of insulin secretion from the beta cells. Thus, inactivating mutations in HADH would lead to a 
loss of the inhibitory protein interaction and an uncontrolled secretion of insulin [44].  
 
Notably, the activating mutations in the GDH-encoding gene GLUD1 also cause CHI (Chapter 
1.2.2.2) [38]. CHI patients with mutations in either GLUD1 or HADH are responsive to 
diazoxide treatment [29]. This is consistent with the fact that GDH lies upstream of the KATP 
channels in the pathway that triggers insulin secretion. Moreover, children with SCHAD CHI 
experience protein-induced hypoglycaemia [45], which might be explained by the role of 






However, the mechanism by which SCHAD regulates insulin secretion and the downstream 
events are not completely understood. It was first suggested that the loss of inhibition on GDH 
by SCHAD results in increasing oxidation rates of glutamate to α-ketoglutarate (α-KG). α-KG 
enters the TCA cycle, increasing the production of ATP, and as a result insulin is released 
(Figure 1.9B) [38]. However, some experimental evidence indicates that – specifically in beta 
cells - GDH favours the opposite direction of this reversible reaction (e.g. glutamate formation) 
as a consequence of the beta cell NADH/NAD+ ratio [47]. The produced glutamate would then 
be taken up by insulin secretory granules, which leads to amplification of insulin secretion 





Figure 1.9 – Proposed mechanisms of insulin dysregulation in SCHAD deficiency. Under normal conditions SCHAD 
interacts with GDH and inhibits its enzymatic activity. A) GDH converts α-KG to glutamate, which is taken up by the secretory 
granules. The uptake of glutamate leads to amplification of the insulin secretion. The fate of α-KG depends on the ratio of 
NADH to NAD+.  B) Loss of inhibition of SCHAD on GDH result in a gain of GDH activity, which increases the oxidation of 
glutamate to α-KG. α-KG enters the TCA cycle, the production of ATP increases, and insulin is released.   
 
 
In addition to the interaction with GDH, there is evidence of SCHAD could be involved in a 
large tissue-specific metabolic super complex where several metabolic pathways might 
converge [44]. The complex might involve several key regulatory enzymes from fatty acid 
oxidation, ketogenesis, amino acid catabolism, ureagenesis and glycolysis. This suggests that 
SCHAD might have additional organizational, structural and/or non-enzymatic roles, even 





1.4 Classification of pathogenic variations in human genes  
On average, the human genome has a variation in base sequence every few hundred bases. 
Variants can occur both in coding and non-coding areas. The 1000 Genomes project 
(http://www.internationalgenome.org) has estimated that an individual has 10000-11000 
variants that change the amino acid sequence of proteins, and additional 10000-12000 exonic 
variants that have no effect. Approximately 50-100 variants per individual are associated with 
inherited disorders, but most individuals will only be carriers of the disease  [51].  
 
With the increasing use of whole-genome sequencing, variants are being discovered in the 
human genome at a high rate. This leads to a high demand to determine the clinical significance 
of a given variant. The American College of Medical Genetics and Genomics and the 
Association for Molecular Pathology have made a joint consensus for standards and guidelines 
for the interpretation of sequence variants. This includes a five-tier system of classification and 
can be used on all Mendelian genes. In the approach, criteria (evidence) of different strength 
are combined to determine the pathogenicity class of a variant (Table 1.2). Variants are then 
classified from 1-5 with the following designations: (1) pathogenic, (2) likely pathogenic, (3) 
uncertain significance, (4) likely benign, and (5) benign. The term “likely” means a greater than 




Table 1.2 - Criteria of different strength to determine pathogenicity. Criteria for benign to the left and pathogenic to the 















1.4.1 Pathogenic variants of SCHAD   
To date, there are 45 published patients with CHI caused by mutations in the HADH gene. Table 
1.3 contains a list of the patients. All listed HADH mutations have an autosomal recessive 
inheritance. Dominantly acting mutations of this gene have not been seen.  
 
Table 1.3 – Published patients with CHI caused by mutations in the HADH gene. The mutations are reported at the DNA 
level for splice site and intronic mutations, while the resulting effect on the protein is reported for those affecting the coding 
regions directly. NA = no information. Table adapted from [34].  
Patient Gender Consanguinity  Ethnicity Onset Mutation Reference 
1 F No  Indian 4 moths P258L [31] 
2 M Yes  Pakistani 3 days IVS4-
3DELCAGGTC 
[32] 
3 F Yes  Pakistani 1.5 hours IVS4-
3DELCAGGTC 
[32] 
4 M Yes  Pakistani 4 months IVS6-2A>G [53] 
5 F No  Caucasian 10 months D57G, Y226H [54] 
6 F Yes  Bangladeshi 4 months M188V [46] 
7 M Yes  Caucasian 2 months R236X [55] 
8 M Yes  Caucasian 8 months S196FfsX3 [56] 
9 F Yes  Caucasian 6 months S196FfsX3 [56] 
10 M NA  Caucasian 14 months S196FfsX3 [56] 
11 M No  Caucasian 7 months IVS2+1G>A [56] 
12 M Yes  Turkish 16 weeks K136E [57] 
13 M Yes  Turkish 16 weeks Q163X [57] 
14 M Yes  Turkish 2 weeks R236X [57] 
15 M Yes  Turkish 5 days R236X [57] 
16 F No  Turkish 1 week R236X [57] 
17 M Yes  Pakistani 2 days R236X [57] 
18 F No  Iranian 12 weeks R236X [57] 
19 F No  Iranian 1 day R236X [57] 
20 M No  Indian 26 weeks K95SfsX3, 
IVS6 + 39C>G 
[57] 
21 M No  Indian 2 days Ex1deletion [57] 
22 M No  Indian 24 weeks Ex1deletion [57] 
23 NA NA  NA NA G34R [30] 
26 
 
24 NA NA  NA NA K95fs [30] 
25 NA NA  NA NA IVS8+39C>G [30] 
26 F NA  Chinese NA R10P, 
V30E 
[58] 
27 F No  Indian 12 weeks I184F [16] 
28 F No  Indian 16 weeks I184F [16] 
29 M Yes  Saudi 16 weeks IVS2-1G>A [59] 
30 F Yes  Saudi 12 weeks IVS2-1G>A [59] 
31 M Yes  Saudi 16 weeks IVS2-1G>A [59] 
32 F No  Turkish 4 weeks IVS2-1G>A [60] 
33 M Yes  Iranian 12 weeks IVS2-1G>A [61] 
34 F Yes  Iranian 1 year IVS2-1G>A [61] 
35 M Yes  Iranian 1 day IVS2-1G>A [61] 
36 F Yes  Iranian 4 days IVS2-1G>A [61] 
37 M Yes  Iranian 12 weeks IVS2-1G>A [61] 
38 M Yes  Iranian 6 weeks IVS2-1G>A [61] 
39 M Yes  Iranian 30 weeks IVS2-1G>A [61] 
40 F Yes  Iranian 1 day IVS2-1G>A [61] 
41 M Yes  Iranian 12 weeks IVS2-1G>A [61] 
42 M Yes  Iranian 12 weeks IVS2-1G>A [61] 
43 M Yes  Iranian 12 weeks IVS2-1G>A [61] 
44 M No  Caucasian NA G303S [62] 












2. Aims of the study 
 
The overall objective of this thesis was to functionally characterize different rare variants of the 
SCHAD protein to obtain a better understanding of how this protein is involved in insulin 
secretion.  
 
The specific sub-aims of the project were:  
1. To express four rare SCHAD variants, reported as pathogenic, in bacterial and 
mammalian plasmid vectors  
2. To evaluate the expression level, cellular localization, and enzymatic activity of the 
aforementioned four variants in vitro  
3. To compare the protein stability of a series of rare SCHAD variants in human cells 
4. To assess the interaction between a series of rare SCHAD variants and glutamate 
dehydrogenase  
5. Based on the results, to make a formal classification of the degree of pathogenicity 































Table 3.1 – DNA techniques. 
Material  Catalogue number Supplier 
1 kb DNA Ladder  N3232S New England BioLabs  
100 bp DNA Ladder N3231S New England BioLabs 
2-propanol I9516-500ML Sigma Aldrich 
Ampicillin sodium salt A9518-5G Sigma Aldrich 
BL21 (DE3) competent E.coli cells C2527I New England Biolabs  
CutSmartTM buffer B7204S New England BioLabs 
D-(+)-Glucose powder G7021 Sigma Aldrich 
EcoRI-HFTM R3101S New England BioLabs  
Ethidium Bromide (10 mg/ml) 161-0433 Life Technologies 
Gel Loading Dye Blue (6x) B7021S New England BioLabs 
HisSpeed Plasmid midi kit  12643 Qiagen  
ImMediaTM Amp Agar 45-0034 Invitrogen 
ImMediaTM Kan Agar 45-0043 Invitrogen  
Kanamycin Sulfate (100x) 15160-054 Life Technologies 
LB broth (Lennox) growth medium L7275-500TAB Sigma Aldrich 
NuSieveTM GTGTM Agarose 50084 Lonza 
SOC Outgrowth medium B9020S New England Biolabs 
TBE Buffer (10X) A3945 PanReac AppliChem 




Table 3.2 – Plasmids. 
Plasmid Description Supplier 
pcDNA3.1 Empty vector Invitrogen  
pcDNA3.1- SCHAD-V5 SCHAD-V5 Made by group  
pET-MBP-SCHAD MBP-SCHAD  Gift from Thomas Arnesen, 
University of Bergen 
Plu-CMV-wt-hGDH-mCherry Human GDH Gift from Chonghong Li, 








Table 3.3 – Cell lines. 
Cell line Description Catalogue number Supplier 
HEK293 Human embryonic kidney cells 632180 Clontech 
HEK293 SCHAD        
KO 
Human embryonic kidney cells 
with SCHAD knock out 
- Knock out done by  





Table 3.4 – Reagents for cell culturing and transfection. 
Material Catalogue number Supplier 
CountessTM cell counting chamber slides C10283 Invitrogen 
Dimethyl sulfoxide (DMSO) D2650-5X5ML Sigma Aldrich  
Dulbecco’s Modified Eagle’s Medium (DMEM) 41966-029 Gibco 
Dulbecco’s Phosphate Buffered Saline (PBS) D8537 Sigma Aldrich 
Fetal Bovine Serum (FBS) 10270-106 Gibco 
OPTI-MEM® I (1X) 31985-062 Life Technologies 
Penicillin-Streptomycin (PenStrep) P4458 Sigma Aldrich 
Trypan Blue stain 0.4% T10282 Invitrogen  
Trypsin-EDTA solution T3924 Sigma Aldrich  
HEPES H2275-25G Sigma Aldrich 
CaCl2  442909-1KG Sigma Aldrich 




Table 3.5 – Antibodies. 
Antibody Catalogue number Supplier Dilution Classification 
Anti-β-Tubulin (rabbit) Ab6046 Abcam 1:30000 Primary 
Anti-GLUD1 (rabbit)  Ab166618 Abcam 1:1000 Primary 
Anti-Mouse (goat)  626520 Invitrogen  1:5000 Secondary 
Anti-Mouse Alexa Fluor 488 (goat)  Ab150113 Abcam 1:2000 Secondary 
Anti-Rabbit (goat)  656120 Invitrogen 1:5000 Secondary 










Table 3.6 – Site directed mutagenesis. 
Material Catalogue number Supplier 
DpnI (10 U/μl) 200518-52 Agilent Technologies 
QuickChange II XL Site-Directed                                 
-----Mutagenesis Kit 
200522-5 Agilent Technologies 
QuickChange XL dNTP Mix 200516-52 Agilent Technologies 




Table 3.7 – Sanger Sequencing. 
Material Catalogue number Supplier 
BigDye CTerminator® Purification kit 4376486 Thermo Fischer  
BigDye® Terminator v1.1 Cycle                    
-----Sequencing Kit 




Table 3.8 – Primers used for PCR amplification and Sanger Sequencing. 
Primer Direction Sequence (5’ to 3’) 
G34A Forward CAGCCCGCCGCGGATGACCGTCA 
G34A_as Reverse TGACGGTCATCCGCGGCGGGCTG 
HADH seq 3 Forward CAGACAAGACCGATTCGCT 
HADH seq 6 Reverse CGATGACCGTCACGTGCTT 
HADH seq 8 Forward GAGAAGACCCTGAGCACCAT 
HADH seq10 Reverse GGATGTCCTCTGTCTGGTCT 
HADH seq11 Reverse CCAGGAGGCGGTTCACAATA 
HADH-V5 Forward AGGCTGTATGAACGAGGTGA 
HADH-V5 Reverse GGAGAGGGTTAGGGATAGGC 
I184F Forward CTGGTCATTGGTGTTTTAAAGACCTCCACAAGTTTCATG 
I184F_as Reverse CATGAAACTTGTGGAGGTCTTTAAAACACCAATGACCAG 
K136E Forward TATGTTCAGCAGCAAACTCGTCCAGCCTTTTGAAGAG 
K136E_as Reverse CTCTTCAAAAGGCTGGACGAGTTTGCTGCTGAACATA 
M188V Forward CTTCTGGCTGGTCACTGGTGTTTTAATGACCTCC 
M188V_as Reverse GGAGGTCATTAAAACACCAGTGACCAGCCAGAAG 
pcDNA_HADHpl_FW Forward GCACCAAAATCAACGGGACT 
pcDNA_HADHpl_RV Reverse TTGTCTTCCCAATCCTCCCC 
β-actin Forward CTGGGACGACATGGAGAAAA 






Table 3.9 – Cell lysis, SDS-PAGE and Western Blotting.  
Material Catalogue number Supplier 
Blotting-Grade Blocker nonfat dry milk 170-6404 Bio-Rad 
c0mplete Tablets, Mini EASYpack 04693124001 Sigma Aldrich 
ECL SelectTM Western Blotting Detection Reagent  RPN2235 GE Healthcare  
ECLTM Primer Western Blotting Detection Reagent RPN2232 GE Healthcare  
Immun-Blot® PVDF Membranes for Protein Blotting 1620177 Bio-Rad 
Methanol  A456-212 Thermo Fisher Scientific 
NuPAGE® Antioxidant NP0005 Thermo Fisher Scientific 
NuPAGE® LDS Sample Buffer (4x) NP0007 Thermo Fisher Scientific 
NuPAGE® MOPS SDS Running Buffer (20x) NP0001 Thermo Fisher Scientific 
NuPAGE® Reducing Agent (10x) NP0009 Thermo Fisher Scientific 
NuPAGE® Transfer Buffer (20x) NP0006-1 Thermo Fisher Scientific 
NuPAGETM 10% Bis-Tris Gel 1.0 mm x 10 well NP0301BOX Thermo Fisher Scientific  
NuPAGETM 10% Bis-Tris Gel 1.0 mm x 15 well NP0303BOX Thermo Fisher Scientific  
Phosphate Buffer saline (PBS) Tablets 18912-014 Life Technologies 
Pierce® RIPA Buffer, 100 ml 89900 Thermo Scientific  
PierceTM BCA Protein Assay Kit 23227 Thermo Scientific  
Precision Plus ProteinTM Standards All Blue 161-0373 Bio-Rad 
RestoreTM PLUS Western Blot Stripping Buffer 46430 Thermo Scientific 
SimplyBlueTM Safestain  LC6065 Life Technologies  
Tween ® P5927 Sigma Aldrich 
Western Blotting Filter Paper, 7cm x 8.4cm  84783 Thermo Scientific  
XCell SureLock™ Mini-Cell and XCell II™ Blot         
-----Module 
EI0002 Thermo Fisher Scientific 
 
 
Table 3.10 – Immunofluorescence. 
Material Catalogue number Supplier 
Bovine Serum Albumin (BSA)  A7030-50G Sigma Aldrich 
Cover slips (18 mm) 117580 Werderop Werd 
Ethanol pure 20821 VWE  
Formaldehyde solution 252549-IL Sigma-Aldrich  
Glycine 50052-1KG Fluka Analytical 
MitoTracker® Red CMXRos M7512 Thermo Fisher lb  
Mounting glass  2009-08 Thermo Scientific  
Poly-L-lysine  P4832-50ml Sigma Aldrich  
ProLong® Gold antifade reagent with DAPI P36935 Life Technologies 




Table 3.11 – TNT assay. 
Material Catalogue number Supplier 






Table 3.12 – Reverse Transcriptase PCR. 
Material Catalogue number Supplier 
dNTP Mixture 4030 TaKaRa Clonetech 
High Capacity cDNA Reverse Transcription Kit 4374966 Applied BiosystemsTM 
LA Taq® DNA Polymerase with GC Buffer RR02AG TaKaRa Clonetech 




Table 3.13 – Protein purification and enzymatic assay  
Material Catalogue number  Supplier  
Acetoacetyl-CoA A1625-5MG Sigma Aldrich 
DTT 43816-10ML Sigma Aldrich 
Glycerol G2025-1L Sigma Aldrich  
HiLoad 16/60 Superdex 200 prep grade 28989335 GE Healthcare Life Sciences 
HisTrapHP 17-5248-01 GE Healthcare Life Sciences 
Imidazole AC122020020 ACROS Organics  
IPTG  I6758 Sigma Aldrich 
K2HPO4 105101 Merck  
KH2PO4 104873 Merck  
MES hydrate M5287-250G Sigma Aldrich 
NaCl 793566-2.5KG Sigma Aldrich  
NADH N1161-10V Sigma Aldrich 
NaH2PO4 71507 Sigma Aldrich  
NaOH 0402 J.T. Baker  
Peptone 70172-500G Fluka Analytical  
Protease inhibitors cOmplete, EDTA free 11873580001 Roche 






Table 3.14 - Cycloheximide chase assay 
Material Catalogue number  Supplier  




Table 3.15 - Co-immunoprecipitation assay. 
Material Catalogue number Supplier 




Table 3.16 – Buffers and solutions. 
Buffers and solutions  Use Composition  
10% Transfer buffer Western Blotting 50 mL NuPAGE® MOPS transfer buffer (20x), 1 
ml NuPAGE® Antioxidant, 100 ml methanol, 849 
ml deionized water 
2x HBS buffer, pH 7  Transfection  50 mM HEPES, 280 mM NaCl, 1.5 mM Na2HPO4, 
dissolved in Mq H2O, pH 7 
Blocking buffer Immunofluorescence 5 ml 4% BSA solution, 4.5 ml 100 mg/ml glycine 
solution, 10.5 ml PBS-Tween  
Elution buffer Protein purification 50  mM NaH2PO4, 300 mM NaCl, 250 mM 
Imidazole, 10% glycerol, 0.1 mM DTT, ddH2O to 
total volume 80 ml, pH 7.9  
Enzymatic assay buffer Enzymatic assays 0.1 M potassium phosphate buffer pH 7.0, 0.1 mM 
DTT, 0.3 mg/ml BSA, 50 μM Acetoacetyl-CoA, 
0.15 mM NADH 
Gel filtration buffer Protein purification 50 mM NaH2PO4, 150 mM NaCl, 10% glycerol,0.1 
mM DTT,  ddH2O to total volume of 500 ml, pH 
7.9 
Lysis buffer Protein purification 50 mM NaH2PO4, 500 mM NaCl, 10 mM 
Imidazole, 10% glycerol, 0.1 mM DTT, ddH2O to 
total volume 100 ml, pH 7.9 
PBS-Tween (0.1%) Immunofluorescence, 
Western Blotting 
PBS tablets and 10% Tween dissolved in mqH2O 
Permeabilization buffer  Immunofluorescence 0.4 ml 10% Triton-X-100, PBS to 20 ml 
Washing buffer Protein purification 50 mM NaH2PO4, 300 mM NaCl, 20 mM 
Imidazole, 10% glycerol, 0.1 mM DTT, ddH2O to 
total volume 150 ml, pH 7.9 
Potassium phosphate 
buffer 
Enzymatic assay  15.38 ml K2HPO4, 7.7 ml KH2PO4, adjust to pH 7.0 
with NaOH, ddH2O to total volume 250 mL  
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Table 3.17 - Technical equipment. 
Instrument  Manufacturer  
Applied Biosystems 3500xL Genetic Analyzer Thermo Fischer  
BioTek™ ELx808™ Absorbance Microplate Reader Fischer Scientific  
CountessTM Automated Cell Counter Invitrogen 
Eclipse E800 Microscope Nikon 
GBOX I Chemi XR5 Syngene  
GeneAmp® PCR System 2700 Applied Biosystems  
GeneFlash ABI 3500xl Syngene  
Leica Confocal SP5 Leica Microsystems  
MBA 2000 UV/VIS Spectrophotometer Perkin Elmer 
NanoDrop ND-1000 Spectrophotometer  Thermo Fischer Scientific  




Table 3.18 - Analytical Software. 
Software  Supplier  
Alamut® Visual  Interactive Biosoftware  
GIMP 2 (GNU Image Manipulation Program) GIMP 
Image StudioTM Lite LI-COR®  
InkScape 0.92.2 InkScape  
Leica Application Suite X (LAS X) Leica Microsystems 
PyMOL Schrödinger  
QuickChange Primer Design Agilent  
























4.1 Construction of four new SCHAD variants  
4.1.1 Primer design 
Primers needed for the construction of four new SCHAD variants (Table 4.1) were designed 
using the web-based QuickChange Primer Design Program from Agilent 
(https://www.genomics.agilent.com/primerDesignProgram.jsp). Primers were dissolved in TE 
buffer to a 100 μM concentration and stored at -20˚C. 
 
Table 4.1 – Sequences of primers used to construct the four SCHAD variants G34R, K136E, I1844F and M188V. 
Primer Sequence (5’ to 3’) 
G34R  CAGCCCGCCGCGGATGACCGTCA 
G34R_as  TGACGGTCATCCGCGGCGGGCTG 
K136E  TATGTTCAGCAGCAAACTCGTCCAGCCTTTTGAAGAG 
K136E_as  CTCTTCAAAAGGCTGGACGAGTTTGCTGCTGAACATA 
I184F  CTGGTCATTGGTGTTTTAAAGACCTCCACAAGTTTCATG 
I184F_as  CATGAAACTTGTGGAGGTCTTTAAAACACCAATGACCAG 
M188V  CTTCTGGCTGGTCACTGGTGTTTTAATGACCTCC 
M188V  GGAGGTCATTAAAACACCAGTGACCAGCCAGAAG 
 
 
4.1.2 Site-directed mutagenesis  
The four missense mutations were introduced in the mammalian pcDNA3.1-SCHAD-V5 
(Figure 4.1A) and the bacterial pET-MBP-SCHAD (Figure 4.1B) expression vectors by the use 
of the QuickChange II XL Site-Directed Mutagenesis Kit from Agilent Technologies. 
  
 




The reaction mixes for the mutagenesis reactions were prepared as shown in Table 4.2, and 
PCR amplifications were run as shown in Table 4.3.   
 
Table 4.2 – Master mix components for site directed mutagenesis. 
Component Volume 
10 x reaction buffer 5.0 μl 
DNA template 10.0 ng 
Reverse primer (10 μM) 1.25 μl 
Forward primer (10 μM) 1.25 μl 
dNTP mix 1.0 μl 
QuickSolution reagent 3.0 μl 
PfuUltra High Fidelity DNA Polymerase 1.0 μl 
MQ H2O To final volume of 50.0 μl 
 
 
Table 4.3 – Amplification conditions for site-directed mutagenesis. 
Step Temperature (˚C) Duration Cycles 
Pre-denaturation 95 1 min 1 




Annealing 60 50 sec 
Elongation 68 1 minute / kb plasmid length: 
SCHAD-V5 = 6 min 24 sec 
MBP-SCHAD = 6 min 54 sec 
Final elongation 68 7 min 1 
Cooling 4 ꚙ  
 
To digest parental methylated and hemimethylated dsDNA, 1 μl DnpI restriction enzyme (10 
U/μl) was added to each amplification reaction. The samples were incubated at 37˚C for 1 hour.  
 
4.1.3 Transformation of XL10-Gold Ultracompetent Cells  
The DpnI-treated reactions were used for transformation into XL10-Gold Ultracompenent cells 
by the heat shock method. Two μl β-mercaptoethanol was added to 45 μl bacteria cells and 
incubated on ice for 10 minutes. Two μl of DpnI-treated DNA was added to the cells, followed 
by incubation on ice for 30 minutes. Cells were heat-shocked at 42˚C for 30 seconds, and after 
2 minutes of incubation on ice, 0.5 ml preheated SOC medium was added to the tube. Cells 
were incubated for 1 hour at 37˚C on vigorous shaking (250 rpm), before plating 80 μl of the 
transformation reaction on selective agar plates (MBP-SCHAD = kanamycin, V5-SCHAD = 
ampicillin). After approximately 16 hours, 2 ml selective LB medium was inoculated by one 
bacteria colony. The starter culture was incubated for 8 hours at 37˚C with vigorous shaking 
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(250-300 rpm) before diluting it 1/1000 in 50 ml selective LB medium. The culture was grown 
overnight and harvested by centrifugation at 4000 g for 20 minutes. The supernatant was 
removed and the pellet was frozen at -20˚C until further use. Plasmid purification was 
performed as described in Chapter 4.2.1.  
 
4.1.4 Sanger Sequencing 
After preparation, all plasmids were verified by Sanger sequencing by the use of the BigDye 
Terminator v.1.1 Cycle Sequencing Kit. Sequencing mixes were made as shown in Table 4.4. 
Separate mixes were made for each of the primers. Their target sequences are shown in Table 
4.5. The thermal amplification program is presented in Table 4.6. 
 
Table 4.4 – Components for Sanger sequencing. 
Reagents Volume 
BigDye Terminator v.1.1 Ready Reaction mix 1.0 μl 
BigDye Terminator v.1.1 5x Sequencing Buffer 2.0 μl 
Sequencing primer (2 μM) 1.0 μl 
Plasmid 2.0 μl 
MQ H2O 4.0 μl 
Final volume 10.0 μl 
 
 
Table 4.5 – Primers used for sequencing of SCHAD variants. 
Primer DNA target sequence (5’ to 3’) 
HADH Seq 3 CAGACAAGACCGATTCGCT 
HADH Seq 6 CGATGACCGTCACGTGCTT 
HADH Seq 8 GAGAAGACCCTGAGCACCAT 
HADH Seq 10 GGATGTCCTCTGTCTGGTCT 





Table 4.6 - Thermal amplification cycles for Sanger sequencing. 
Step Temperature Duration Cycles 
Pre-denaturation 96˚C 1 min 1 
Denaturation 96˚C 10 sec  
25 cycles Annealing 50 ˚C 5 sec 
Elongation 60˚C 4 min  




After the PCR amplification, 15 μl MQ H2O was added to each reaction before proceeding to 
PCR purification by the use of a Bigdye XTerminator Kit. Forty-five μl SAM solution and 10 
μl BigDye XTerminator bead solution were added to 10 μl of the amplified sample in a 96-well 
sequencing plate. A MicroAmp Clear Adhesive Film was used to seal the samples, and the plate 
was shaken at 1800 rpm for 20 minutes. The reactions were then centrifuged for 2 minutes at 
1000 g, and placed in a capillary electrophoresis instrument used for sequencing (GeneFlash 
ABI 3500xl). Sequences were analysed using the sequencing analysis program SnapGene.  
 
 
4.2 Plasmid purification and evaluation of DNA quality  
4.2.1 Plasmid purification 
Plasmids were purified from a 50 ml overnight culture by the use of a HiSpeed Plasmid Midi 
Kit. The purification was performed as described in the manufacturer’s handbook (May, 2012). 
In short, pelleted bacterial cells were resuspended in resuspension buffer (with RNase A), and 
lysed in alkaline lysis buffer (with NaOH and SDS). After addition of neutralization buffer, 
precipitates were cleared from the lysate by filtrating through a QIAfilter Cartridge. Plasmid 
DNA was then filtered from the lysate by a HiSpeed Tip by gravity flow. After washing, the 
plasmid DNA was eluted in a high-salt buffer and concentrated by isopropanol precipitation. A 
QIAprecipitator Module was used to collect the DNA, and the DNA was eluted with 1 ml buffer 
TE.  
 
4.2.2 OD measurements 
The concentration and purity of the plasmid DNA preparations were measured by the use of 
NanoDrop ND-1000 spectrophotometer. The concentration in a sample was determined as the 
average of three measurements. A preparation with a 260/280 nm absorbance ratio around 1.8 
to 2.0 was considered of sufficient purity.  
 
4.2.3 Agarose gel electrophoresis  
To further evaluate the quality of the plasmid preparation, untreated samples and samples 
treated with a restriction enzyme were subjected to electrophoresis in a 1% agarose gel 
containing 0.5 μg/ml ethidium bromide. Restriction digestion with EcoRI, which has a unique 
cutting site in the plasmids, was used to confirm that they had the expected size. Samples were 
prepared as shown in Table 4.7. The cut plasmid reactions were incubated at 37˚C for 15 
minutes before adding the loading buffer.  
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Table 4.7 – Sample preparation for restriction digestion and agarose gel electrophoresis. 
 
Samples were run adjacent to a 1 kb DNA ladder to estimate the size of the fragments. The gel 
was run at 90V for 1-2 hours in 1x TBE buffer.  
 
4.3 Cell culture and transfection 
4.3.1 Culturing 
Human Embryonic Kidney cells (HEK293) were cultured in DMEM supplemented with 10% 
FBS and 1% Penicillin Streptomycin (Pen Strep). The cells were incubated in humidified air at 
37˚C with 5% CO2. All work was done in a sterile hood. Standard HEK293 cells and HEK293 
SCHAD KO cells were cultured under the same conditions.  
 
4.3.2 Culture maintenance and sub-culturing 
Cells were split twice a week when the confluency was 80-90%, and in addition the medium 
was changed once in between. Cells were grown in either T75 or T25 flasks. Upon splitting, 
cells were washed in PBS and detached from the flask with 0.05% Trypsin-EDTA solution 
(T75 = 5 ml, T25 = 1 ml). After a 5-minute incubation period, fresh medium (T75 = 7 ml, T25 
= 4 ml) was added to the cells and a homogenous cell suspension was made by pipetting.  Cells 
were diluted 1/10 in fresh medium (total volume T75 = 10 ml and T25 = 5 ml) and seeded 
again. The remaining cells were used in experiments or discarded.  
 
4.3.3 Cell counting 
After trypsinization, cells were counted in a Countess automated cell counter machine. To be 
able to estimate cell viability, 15 μl of the cell suspension was mixed with equal amounts of 
Trypan Blue. Ten μl of the mix was added to each of two separate chambers in a counting cell 
which was then inserted in the machine to proceed with the quantification. The average value 
of viable cells for both chambers was calculated and used as the cell number. 
 
Component Cut plasmid Uncut plasmid 
Plasmid 250.0 ng 100.0 ng 
10x Cutsmart buffer 5.0 μl - 
EcoR1 1.0 μl - 
6x Loading dye 10.0 μl 1.0 μl 
MQ H2O To final volume of 50.0 μl To final volume of 6.0 μl 
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4.3.4 Freezing and thawing  
For freezing, cells from one T75 flask were trypsinized and resuspended in 5 ml complete 
medium. The cells were spun down at 200 g for 5 minutes and the supernatant was removed. 
The pellet was then re-suspended in 3 ml freezing medium (10% (v/v) DMSO in complete 
medium). This cell suspension was then divided in 1 ml aliquots in cryo-vials and placed in a 
Coolcell. The Coolcell was kept at -80˚C overnight, before transferring the vials to liquid 
nitrogen for long term storage.   
   
To start a new culture, a vial was removed from liquid nitrogen and the cell suspension was 
rapidly thawed by hand-warming, before transferring the content to a tube containing 9 ml 
complete growth medium. Cells were spun down for 5 minutes at 125 g before removing the 
supernatant. The pellet was resuspended in 10 ml complete media and the whole volume was 
transferred to a T75 flask.  
 
4.3.5 Transient transfection of HEK293 cells  
4.3.5.1 Transfection by the calcium phosphate method 
Transfection of plasmids to HEK293 cells grown in 10 cm petri dishes was done by the calcium 
phosphate method. Two solutions, A and B, were prepared in separate tubes as shown in Table 
4.8. Solution B was added dropwise to solution A while vortexing, and the mix was incubated 
at RT for 5 minutes. The solution was then added drop-wise directly to the medium of the cells 
and evenly distributed in the plate. After 4 hours of incubation at 37˚C with 5% CO2 the 
transfection medium was replaced with 10 ml fresh medium. The cells were harvested 
approximately 48 hours after transfection. 
 
Table 4.8 – Components for transfection by the calcium phosphate method.  
Solution Component Volume 
A 2x HBS 600.0 μl 
 
B 
Plasmid 10.0 μg 
CaCl2 72.3 μl 
MQ H2O To final volume of 600.0 μl 
 
4.3.5.2 Transfection using Lipofectamine  
Cells grown in 6- and 12-well plates were transfected by the Lipofectamine method at a 
confluency of 60-70%. OptiMEM (12-well = 50 μl, 6-well = 100 μl) was added to two 1.5 ml 
tubes. DNA (12-well = 1 μg, 6-well = 4 μg) was added to one of the tubes, while Lipofectamine 
(12-well = 4 μl, 6-well = 10 μl) was added to the other. The DNA mixture was then added to 
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the Lipofectamine mixture and incubated at RT for 5 minutes, before equally distributing the 
solution directly in the medium of the cells. After 4 hours the medium was exchanged by fresh 
medium.  
 
4.4 SDS-PAGE and western blotting  
4.4.1 SDS-PAGE 
In general, samples for SDS-PAGE were prepared with a protein concentration ranging from 
1-5 μg in a total volume of 10-20 μl with 1x loading buffer and reducing agent. Samples were 
denatured on a heating block at 70-90˚C for 10-20 minutes. For separation by gel 
electrophoresis, samples were loaded in 10% NuPage Bis-Tris gels adjacent to 3 μl Precision 
Plus Protein standard. Five-hundred μl NuPAGE Antioxidant were added to the running buffer 
in the inner buffer chamber of the XCell SureLock Mini-cell.  Gels were run in 1x MOPS 
NuPAGE SDS running buffer for approximately 75 minutes at 160V.  
 
4.4.2 Coomassie staining 
Gels were stained using SimplyBlue SafeStain according to the manufacturers microwave 
procedure (February, 2012). After electrophoresis, the gel was placed in approximately 100 mL 
ddH2O and microwaved until the solution almost boiled. The gel was shaken on an orbital 
shaker for 1 minutes before discarding the water and repeating the above steps two times. 
Approximately 20 ml SimplyBlue SafeStain was then added to the gel. After microwaving for 
45 seconds, the gel was incubated in the solution at shaking for 5 minutes.  Finally, the gel was 
washed in ddH2O for 10 minutes, and imaged on a GBOX I Chemi XR5 instrument.  
 
4.4.3 Western blotting 
Proteins were transferred to a polyvinylidene fluorid (PVDF) membrane (pre-activated in 
methanol) in NuPage transfer buffer for 70 minutes at 30 V according to the manufacturer’s 
instructions using the XCell II Blot Module. Following transfer, membranes were blocked in 
3% dry milk diluted in PBS-Tween for 1 hour at RT. Antibodies were diluted in the same 
solution. Primary antibodies were incubated for 1 hour at RT or overnight at 4˚C, and secondary 
horseradish peroxidase (HRP) conjugated antibodies for 1 hour at RT. The membrane was 
washed in PBS-Tween after each antibody incubation (4 x 15 min). Amersham ECL Prime or 
Select Western Blotting Detection Reagent were used as substrate for HRP activity from the 




4.5 SCHAD-V5 protein expression level assessment by western blotting  
 
Protein expression of SCHAD-V5 was tested in both standard HEK293 cells and HEK293 
SCHAD KO cells. 1.0x105 cells were seeded per well in a 12-well plate, and after 24 hours, the 
cells were transfected with the Lipofectamine reagent (4.3.5.2).  
 
4.5.1 Lysis of HEK293 cells for protein extraction  
Forty-eight hours post transfection cells were washed twice in PBS and lysed in 100 μl/well 
cold RIPA buffer with 1x protease inhibitor for five minutes. Cells were transferred to 1.5 ml 
tubes and centrifuged at 14000 g for 15 min at 4˚C. The pellet was then discarded, and the 
protein concentration of the supernatant measured by the use of a Bicinchoninic Acid (BCA) 
assay. 
 
4.5.2 Protein concentration determination  
Protein concentration of the cell lysate was measured by the use of a BCA protein assay kit 
following the manufacturer’s instructions. Bovine serum albumin (BSA) standards with a 
concentration ranging from 0.0-2.5 mg/ml were used to make a standard curve. The unknown 
concentrations were determined by interpolation of the graph.  
 
 
4.6 Cell-free protein expression 
The expression of SCHAD-V5 variants was tested using the TNT Coupled 
Transcription/Translation system, which provides all the needed components to produce 
eukaryotic proteins from vectors containing a T7 promoter in a cell-free environment. The 
reaction components were assembled as described in Table 4.9 and incubated at 30˚C for 60 
minutes. Protein synthesis was assessed by western blotting. Samples were prepared as shown 
in Table 4.10, and SCHAD-V5 was detected by anti-V5.    
 
Table 4.9 – Components of the TNT assay. 
Components Volume 
TNT Quick Master Mix 20.0 μl 
Methionine, 1 mM 0.5 μl 
Plasmid DNA template 0.5 μg 






Table 4.10 – TNT sample preparation for western blotting. 
Components Volume 
Reaction sample 3.0 μl 
4x Loading buffer 2.5 μl 
10x Reducing agent 1.0 μl 
MQ H2O 3.5 μl 
Final volume 10.0 μl 
 
 
4.7 Reverse transcriptase PCR of SCHAD variants  
HEK293 SCHAD KO cells (2.5x105) were seeded in a 6-well plate. After 24 hours, the cells 
were transfected with Lipofectamine (Chapter 4.3.5.2). Forty-eight hours after transfection the 
medium was removed and the cells were washed with PBS. Cells were detached with 1 ml 
Trypsin-EDTA and resuspended in 2 ml fresh medium after incubation. The content of each 
well was transferred to separate tubes and centrifuged at 300 g for 5 minutes. The supernatant 
was discarded and the pellet resuspended in PBS. Cell concentrations were determined (Chapter 
4.3.3) to find the volume needed to make aliquots containing 5x105 cells per tube. Once 
aliquoted, cells were pelleted by centrifugation for 5 minutes at 300 g. Supernatants were 
discarded, while the pellets were stored at -80˚C until further use.  
 
RNA was purified from the cell pellets using a RNeasy Micro Kit as described in the 
manufacturer’s handbook (December, 2014). In short, cells were lysed with a guanidine 
thiocyanate buffer (buffer RLT) and homogenized by vortexing. 70% ethanol was added to 
enhance the subsequent binding of nucleic acids to a silica membrane. The sample was then 
added to a spin column containing the silica membrane and the DNA was digested by DNase 
(in buffer RDD). After washing, total RNA was eluted in 30 μl RNase-free water. The 
concentration and quality of the RNA samples were measured with a NanoDrop 
spectrophotometer, and samples were stored at -20˚C until further use.  
 
The purified RNA was used to synthesize single-stranded cDNA using the High-Capacity 
cDNA Reverse Transcription Kit. A master mix was prepared as shown in Table 4.11. Four-
hundred μg RNA was added to 10 μl of the  master mix in equal volume. The samples were 
then centrifuged for 1 minute at 1000 rpm and incubated at 25˚C for 10 minutes, 37 ˚C for 120 




Table 4.11 – Components for cDNA reverse transcription. 
Component Volume/reaction  
10x RT buffer 2.0 μl 
25x dNTP mix (100 mM) 0.8 μl 
10x RT Random Primers 2.0 μl 
MμltiScribe Reverse Transcriptase 1.0 μl 
Nuclease-free H2O 4.2 μl 
Final volume 10.0 μl 
 
The synthesized cDNA was used as a template to amplify the specific products from the 
HADH-V5 constructs by PCR. Actin primers were used as positive and loading controls (see 
list of primers Table 3.8). A PCR master mix was prepared as described in Table 4.12. Two μl 
cDNA template was added to 18 μl of the master mix, and PCR amplification was run as 
described in Table 4.13. 
  
Table 4.12 – Master mix components for cDNA PCR. 
Component Volume  
2xGC buffer 10.0 μl 
dNTP mix (2.5 mM) 3.2 μl 
HADH-V5 (F) primer (20 μM) 0.4 μl 
HADH-V5 (R) primer (20 μM) 0.4 μl 
Β-Actin (F) primer (20 μM) 0.4 μl 
Β-Actin (R) primer (20μM) 0.4 μl 
ddH2O 3.4 μl 
LaTaq enzyme (5U/μl) 0.2 μl 
Final volume 18.4 μl 
 
Table 4.13 – Thermal amplification for cDNA PCR. 
Step Temperature (˚C) Time Cycles 
Pre-denaturation 94 1 min 1 
Denaturation 94 30 sec  
25 Annealing 59 30 sec 
Elongation 72 1 min 30 sec 
Final elongation 72 10 min 1 
Cooling 4 ꚙ  
 
For analysis, the PCR products were run on a 2% agarose gel. Six μl of the PCR products were 
mixed with 3 μl 6x loading buffer and loaded in the wells. A 100 bp DNA ladder was used as 
a marker. The gel was run at 90V for 60 minutes.    
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4.8 Assessment of protein expression and subcellular localization by 
immunofluorescence 
Expression and subcellular localization of the SCHAD-V5 variants were tested by 
immunofluorescence. Before cell seeding, a coverslip was placed in each well of a 12-well 
plate. The coverslips had been previously cleaned and sterilised by washing in ethanol and 
flamed. One ml of poly-L-lysine diluted 1/10 in PBS was added to each well and incubated for 
5 minutes. The slides were then washed twice in PBS and allowed to dry. 1.0x105 HEK292 
SCHAD KO cells were seeded per well. After 24 hours, the appropriate plasmid was transfected 
with Lipofectamine (Chapter 4.3.5.2). After a 48 hours growth period, cells in each well were 
incubated with 1 ml 200 mM Mito Tracker prepared in pre-warmed media for 30 minutes. After 
washing with PBS, cells were fixated by incubation in 1 ml 3.7% paraformaldehyde with 
complete media for 15 minutes and then washed three times in PBS. Cells were permeabilized 
with 500 μl 0.2% Triton X-100 in PBS for 10 minutes under gentle shaking. After 3 x 5 minutes 
washing in PBS, 500 μl blocking buffer was added to each well for 30 minutes under gentle 
shaking. The cells were incubated with primary (anti-V5, 1:500) and secondary (anti-mouse 
Alexa Fluor 488, 1:200) antibodies diluted in PBS in a humidified chamber, each for 1 hour at 
room temperature. The cells were washed 3 x 5 minutes in PBS after the antibodies incubations. 
Finally, coverslips were mounted on a small drop of ProLongGold mounting medium with 
DAPI placed on clean glass slides. Images of the cells were taken using a Nicon Eclipse E800 
fluorescence microscope and a Leica Confocal SP5 microscope.  
 
 
4.9 Cycloheximide chase assay 
3.0 x 105 HEK293 SCHAD KO cells were seeded per well in a 12-well plate. Four wells were 
transfected in parallel per SCHAD-V5 variant (for harvesting at four different time points) with 
Lipofectamine (Chapter 4.3.5.2). Forty-eight hours post transfection, the medium was removed 
and fresh medium with 50 μg/ml cycloheximide was added. Cells were harvested after 0, 2, 8 
and 24 hours. For each time point, the cells were washed twice in ice cold PBS and lysed as 
described in Chapter 4.5.1. The cell lysates were frozen straight after harvesting and the 
centrifugation was performed for all samples in parallel  >24 h post freezing. The protein 
concentration of the cell lysate was measured using the BCA kit (Chapter 4.5.2) and the samples 
were analysed by western blotting as explained in Chapter 4.4.3.  
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4.10 Protein purification and enzymatic assays of MBP-SCHAD  
4.10.1 Transformation of BL21 competent E. coli cells  
Transformation of MBP-SCHAD to competent BL21 (DE3) E .coli cells was done by heat 
shock. A tube of cells was thawed on ice until the last ice crystals disappeared. Around 10 ng 
plasmid DNA was added to the cells bfore the cell mixture was placed on ice for 30 minutes. 
Cells were then heat-shocked at 42 ˚C for 10 seconds and placed on ice for 5 minutes. SOC 
medium (950 μl) at RT was added to the tube, and the mixture was shaken vigorously at 700 
rpm for 60 minutes. Forty μl of cells were spread on previously prepared imMedia Growth 
Medium agar plates (50 μg/ml kanamycin) and incubated overnight at 37˚C. Next morning, the 
plate was placed at 4˚C. A single colony from the plate was inoculated in 10 ml LB medium 
with 1% glucose and 50 μg/ml kanamycin and grown overnight at 37˚C and 250 rpm. The 
starter culture was added to 400 ml LB medium (with glucose and kanamycin) and grown until 
it reached an OD600 of approximately 0.6. After cooling down on ice, the culture was induced 
with 0.1 mM IPTG overnight at 22˚C and 250 rpm. Two-hundred ml aliquots were harvested 
by centrifugation at 4000g for 20 min at 4˚C and subsequently frozen at -20˚C. Two tubes with 
1 ml each were harvested the same way for further analysis. For these samples, the pellet was 
resuspended in 300 μl cold PBS and sonicated for 6 x 15 sec. After centrifugation (15 min at 
10 000 rpm and 4˚C), the supernatant was transferred to a new tube and the pellet was 
resuspended in 300 μl PBS. Ten μl of the samples were mixed with 4 μl loading buffer and 1.6 
μl reducing agent, and analysed by gel electrophoresis. The gel was stained by SimplyBlue 
SafeStain (Chapter 4.4.2).  
 
4.10.2 Protein purification  
Affinity and gel filtration purification of MBP-SCHAD was performed by Kelly Velasco and 
is therefore described in the Appendix. Fractions of interest were analysed by SDS-PAGE 
(Chapter 4.4.1) and SimplyBlue SafeStain (Chapter 4.4.2).  
 
4.10.3 SCHAD enzymatic activity assay  
The enzymatic activity of the purified MBP-SCHAD variants was measured with acetyl-CoA 
as a substrate and NADH as a cofactor. SCHAD catalyses the reversible NAD+-dependent 
dehydrogenation of 3-hydroxyaxyl-CoA to β-ketoacyl-CoA. Both NAD+ and NADH has an 
absorbance maximum at 260 nm, but only NADH has a maximum at 340 nm. The activity of 
SCHAD can most easily be estimated in the reverse reaction by measuring the decrease in 
absorbance at 340 nm, as shown in Figure 4.2. The assay buffer was prepared as shown in Table 
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4.14. NADH was added to the buffer after measuring the blank. The absorbance at 340 nm was 
measured in a UV-visible wavelength spectrophotometer at 37˚C. Purified protein (0.07 μg) 
was added to 1 ml of the assay buffer, and measurements were made every 30 seconds for 5 
minutes.  
 
Figure 4.2 – SCHAD activity. The activity of SCHAD can be measured by the decrease of absorbance at 340 nm. NADH, 
which has an absorbance maximum at 340 nm, is oxidised to NAD+ when SCHAD catalyses the conversion of β-ketoacyl-CoA 




Table 4.14 – Components of the enzymatic assay buffer. 
Components Volume 
Potassium phosphate buffer (0.1 M, pH 7.0) 14.44 ml 
DTT (100 mM) 15.0 μl 
BSA (30 mg/ml) 150.0 μl 
Acetoacetyl-CoA (5 mM) 150.0 μl 
NADH (5 mM)  420.0 μl 
 
 
4.11 Co-immunoprecipitation assay  
Co-immunoprecipitation (Co-IP) was used to assess the ability of the different SCHAD variants 
to interact with GDH. 4.8x106 HEK293 SCHAD KO cells were seeded per 100 mm diameter 
Petri dish. Two Petri dishes were used per Co-IP assay. Ten μg of each plasmid (SCHAD-V5, 
Figure 4.1A; GDH, Figure 4.3) were co-transfected using the calcium phosphate method 
(Chapter 4.3.5.1) in both plates. Forty-eight hours post transfection, the transfection efficiency 
was monitored visualizing the mCherry produced by the GDH plasmid using the fluorescence 
microscope. The medium was removed and the cells were washed once in PBS. Thereafter, the 
plates were kept on ice to avoid protein degradation. Five-hundred μl cold wash/lysis buffer 
(supplemented with protease inhibitor) were added to each plate and incubated for 5 minutes. 
Cells from the two corresponding plates transfected with the same plasmids were collected in 
one tube. Lysates were centrifuged at 13 000 g for 10 minutes at 4˚C before collecting the 




Figure 4.3 – Plasmid map of Plu-CMV-wt-hGDH-mCherry. 
 
To capture protein complexes, a Pierce Co-Immunoprecipitation Kit was used (Figure 4.4). Co-
IP was performed as described in the manufacturer’s instructions, taking into account the 
following:  Cell lysates were pre-cleared by incubation with Control Agarose Resin in a 2 ml 
tube for 30 minutes at 4˚C. From previous measurements, it was known that the lysates from 
one Petri dish usually have a protein concentration around 2 mg/ml. For pre-clearing of the cell 
lysate, 160 μl resin slurry was therefore used per tube. The mixture was centrifuged through a 
column to retain the resin, the flow-through was saved for the Co-IP, and samples were taken 
from the flow-through for later analysis by SDS-PAGE (input sample). Pierce Spin columns 
were used throughout the procedure. All resin centrifugation steps were performed at 3000 g 
for 30 seconds. For the Co-IP, two columns per sample were used: one used to retain the V5-
tagged protein employing an anti-V5 antibody-coupled resin (V5-columns), and a second one 
used as a negative control containing the same kind of resin but without a coupled antibody 
(control columns). V5-columns were prepared as described in the instruction sheet, by coupling 
10 μg of anti-V5 antibody to 50 μl AminoLink Plus Coupling Resin. According to the 
manufacturer, this resin contains high-yield aldehyde-activated agarose beads that covalently 
couples antibodies via primary amines. Control columns were prepared in the same way as the 
V5-columns, but omitting the addition of V5 antibody. The cell lysate containing the transfected 
bait (SCHAD-V5) and prey (GDH) proteins was incubated in the columns for 2 hours at 4˚C. 
After optimization of the manufacturer’s protocol, it was decided to use a total of four washing 
steps before the elution. The linkage between resin and antibodies are stable during the elution 
conditions (non-reducing, non-denaturing). After collection of eluate 1, three additional 
elutions were performed to clear the resin of any remaining bound proteins so they could be re-
used. Between each Co-IP procedure, resins for re-usage were stored in coupling buffer in their 




Figure 4.4 – The procedure of co-immunoprecipitation. A cell lysate is added to a column containing the antibody-coupled 
resin. After several washing steps, the protein complexes are eluted and the eluate is analysed by SDS-PAGE and western 
blotting. Protein (“prey”, here GDH) interacting with the protein captured by the antibody (“bait”, here SCHAD-V5) can 
therefore be detected. Figure from the manufacturer’s protocol (Pierce).   
 
 
For analysis by western blotting, samples were prepared as shown in Table 4.15. SCHAD-V5 
was detected with anti-V5 antibody and GDH with anti-GLUD1 antibody.  
 
 
Table 4.15 – Co-IP sample preparation for western blotting. 
Components Input Elutions 
Sample 5.0 μg 16.3 μl 
4x Loading Buffer 2.5 μl 6.25 μl 
10 x Reducing Agent 1.0 μl 2.5 μl 
MQ H2O To final volume of 10.0 μl - 











4.12 Pathogenicity classification of SCHAD variants  
A set of 16 different SCHAD point-mutations were interpreted by standards and guidelines 
from the American College of Medical genetics (ACMGM) and the Association for Molecular 
Pathology (AMP) (Chapter 1.4) [13]. The Alamut program was used as a support with the 
SCHAD reference sequence NM_005327.4 (NCBI database) chosen as reference. Alamut is a 
mutation analysis program used to explore and classify human genetic variants 
(http://www.interactive-biosoftware.com/alamut-visual/). This software collects information 
from several public databases (for example NCBI, EBI, UniProt and ClinVar) and includes the 
following in-silico tools for missense variant interpretation: PolyPhen-2, SIFT, MutationTaster 
and Align GVGD. SIFT predicts a substitutions effect of protein function based on the 
properties of the amino acid and sequence homology [64], while PolyPhen-2 predicts the impact 
of an amino acid substitution on both structure and function based on evolutionary 
considerations [65].  MutationTaster integrates data from different databases and performs 
analyses regarding conservation, splice-site changes, loss of protein function and changes in 
mRNA level [66]. Align GVGD compares the difference in biochemical properties of the 
original and mutated amino acid and calculate the Grantham’s difference [67], which is a 
measure of the evolutionary distance between two amino acids [68].  Frequency data were 
collected from ExAC (http://exac.broadinstitute.org), GnomAD (http://gnomad.broad 
institute.org/) and 1000 Genomes databases (http://www.internationalgenome.org). The 
localization of the mutated amino acids were assessed to determine if the mutation affected an 



















5. Results  
5.1 Construction of plasmids expressing SCHAD pathogenic variants  
The four variants (G34R, K136E, I184F and M188V) were chosen from case reports of patients 
with CHI caused by SCHAD-deficiency [16, 30, 45, 69]. To construct plasmids expressing 
these variants, each of the desired missense mutations were introduced into two already existing 
vectors expressing the wild type (WT) SCHAD protein. These vectors were pcDNA3.1-
SCHAD-V5 for mammalian expression and pET-MBP-SCHAD for bacterial expression.   
 
The eight plasmids were constructed by site-directed mutagenesis and verified by Sanger 
sequencing. For all plasmids, the whole reading frame of the HADH gene was sequenced to 
check that the desired mutation had been obtained, and that no other mutations had been 
inadvertently introduced. Figure 5.1A is a visualization of the sequencing results for one 
SCHAD-V5 variant (I184F). In Figure 5.1B, the sequence of the region of interest in the 
mutated plasmid is shown along with WT sequence, demonstrating the correct introduction of 




Figure 5.1 – Sequencing results verifying the construction of plasmids expressing HADH variants. Data from the 
construction of the I184F mutation in pcDNA3.1-SCHAD-V5 are shown as example. A) Overview of sequencing data as 
presented by the sequencing analysis program SnapGene. Red arrows indicate the six sequencing reaction products, each 
obtained with a different primer, that together cover the whole HADH gene (gene location shown by purple arrow). A thin, 
white line and star in two of the products indicate that the plasmid contains a mutation in the desired location. B) Nucleotide 
sequence of the region of interest. As shown by comparison with the WT sequence (marked in blue), the nucleotide A has been 








Figure 5.2 shows the location of the four altered amino acids in the structure of the SCHAD 
protein. All of them are positioned in the NAD+-binding domain.  
 
 
Figure 5.2 – Tri-dimensional structure of SCHAD showing how the residues G34, K136, I184 and M188 are located in 
the protein. A) Overall structure. Yellow = signal peptide, green = NAD+-binding domain, blue = dimerization domain.              
B) Close-up of the NAD+-binding domain in which all four altered amino acids are located. In the model, three letter amino 
acid notation has been used, and the methionine 118 has been substituted by selenomethioine (MSE). The image was obtained 




In addition to measuring the concentration and purity of the plasmids using a NanoDrop 
spectrophotometer, all plasmids were subjected to electrophoresis in an agarose gel to further 
assess their quality. Figure 5.3 shows the separation of the SCHAD-V5 variants G34R, K136E, 
I184F and M188V. Restriction digestion was used to confirm that the plasmids had the expected 
size. As shown in the gel, the migration of the cut pcDNA3.1-SCHAD-V5 plasmids (somewhat 
above the 6 kb molecular weight (MW) marker) is consistent with the known size (6427 bp). 
For the uncut plasmids, two bands were observed, one at approximately 6500 bp and a second 
one weaker in intensity at the top of the gel. These two bands might correspond to a supercoiled 
form and a relaxed circular form of the plasmids, which in theory should have a higher and 
lower mobility, respectively, than the linearized form. A possibility is that the low molecular 
band contained a dimerization of supercoiled plasmids and therefor migrated with higher 
molecular weight. The further experiments (described below) confirmed that the plasmids were 
of sufficient quality for our purposes. The same quality control was performed for the pET-




Figure 5.3 – Agarose gel electrophoresis of the pcDNA3.1-SCHAD-V5 plasmid preparations that express the variants 
G34R, K136E, I184F and M188V. The plasmids were digested with the restriction enzyme EcoRI (50 ng loaded) and 
compared to uncut plasmids (100 ng loaded). Plasmids were run on a 1% agarose gel stained with ethidium bromide. The left 




5.2 Mammalian in vitro expression of the four SCHAD variants 
5.2.1 Expression in HEK293 cells and in a cell-free expression system 
To test protein expression of the SCHAD variants in a mammalian cell system, the plasmids 
were transfected into HEK293 cells and the cell lysates were analysed by western blotting. 
Figure 5.4A shows expression of the pathogenic variants compared to the WT SCHAD. Cells 
transfected with the empty vector (pcDNA3.1 without any inserted gene) were included as a 
negative control. The expression was tested both in regular HEK293 cells expressing 
endogenous SCHAD (Figure 5.4A) and HEK293 SCHAD KO cells (Figure 5.4B) where the 
endogenous HADH gene had been disrupted (Johanna Lüdeke, unpublished).  For both cell 
lines, a 37 kDa band corresponding to the expected MW for SCHAD-V5 could be detected 
when the WT, K136E and M188V plasmids were transfected. There was no SCHAD-V5 






To further test the expression of these variants, a cell-free expression system was used (Figure 
5.4C). Now all variants, including G34R and I184F, were detected in similar amounts. This 
result shows that the plasmids expressing the G34R and I184F variants are functional, and may 
indicate the activity of a cellular quality control mechanism, not present in the cell-free 




Figure 5.4 – Mammalian protein expression of SCHAD-V5 WT, G34R, K136E, I184F and M188V. A) Standard HEK293 
cells were transiently transfected with SCHAD-V5 WT, pcDNA3.1 (negative control) and the SCHAD-V5 variants G34R, 
K136E, I184F and M188V. Cells were harvested 48 h post transfection and 2 μg cell lysate was analysed per lane by western 
blotting. SCHAD-V5 was detected with an anti-V5 antibody. Tubulin was used as loading control. SCHAD-V5 was detectable 
in the samples transfected with the WT, K136E and M188V plasmids, but not in the G34R and I184F samples. B) Same 
experiment but performed on HEK293 cells in which endogenous SCHAD expression had been knocked out by the 
CRISPR/Cas9 technique. The expression pattern of the SCHAD variants was similar to the ones seen for regular HEK293 cells. 
C) Western Blot of the SCHAD-V5 variants synthesized using the cell free TNT expression system. All variants now showed 







5.2.2 RNA expression of the HADH variants 
Since no expressed protein could be detected for the variants G34R and I184F in HEK293 cells 
by western blotting, reverse transcription PCR (RT-PCR) was done to investigate the mRNA 
levels of these variants. HEK293 SCHAD KO cells were transiently transfected with the 
SCHAD-V5 variant plasmids, the empty vector (pcDNA3.1) and an additional SCHAD-V5 
variant (G303S) previously constructed in the group (Kelly Velasco, unpublished). The latter 
was known to exhibit considerably lower protein expression than the WT, but similar levels of 
mRNA. It was therefore included for comparison. The cells were harvested 48 h post 
transfection. Total RNA was then extracted from the cells, and RT-PCR was carried out on the 
purified RNA. To detect HADH expression from the cDNA produced, primers that align to a 
region of the HADH gene and a region of the V5 tag were designed. These primers produced a 
304 bp amplicon. An actin primer set that amplifies a 564 bp product was included in the 
reaction, and served both as positive control for the amplification and as loading control. An 
additional negative control using water instead of cDNA template was also included. The PCR 
products were separated by agarose gel electrophoresis and the results are shown in Figure 5.5. 
The intensity of the amplified products for the low-expression variants G34R and I184F was 
similar to the product for the WT. Although the method is not fully quantitative, the results 
suggest that the tested plasmids produce similar amounts of mRNA. Thus, the reduced protein 
expression of G34R and I184F is unlikely to be caused by a technical problem with the plasmids 
or at the transcription level, but most probably by events occurring after protein synthesis. 
 
Figure 5.5 – Electrophoresis of the amplified products from cDNA using HADH-V5 and actin primers. HEK293 SCHAD 
KO cells were transiently transfected with SCHAD-V5 WT, pcDNA3.1, and the SCHAD-V5 variants G34R, I184F and G303S. 
Total RNA was isolated from the cell lysates 48 hours post transfection and cDNA synthesized. cDNA products were amplified 
with primer sets for actin and HADH in a duplex reaction. HADH product length = 304 bp. Actin product length = 564 bp. 1 
kb DNA ladder to the left. Negative control: water sample (Ctrl) and pcDNA.   
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5.2.3 Assessment of protein expression and subcellular localization by immunofluorescent 
staining  
Immunostaining with a fluorescent antibody and confocal imaging were done to further 
investigate the expression and subcellular localisation of the four constructed SCHAD-V5 
variants. HEK293 SCHAD KO cells were transiently transfected with the plasmids and 
immunostained 48 hours post transfection. When looking at the cells at low magnification by 
immunofluorescence microscopy (Figure 5.6) there was a clear difference in the number of 
cells expressing the SCHAD protein. For the two variants K136E and M188V there were quite 
similar numbers of cells expressing SCHAD as for the WT protein. For G34R and I184, 
however, there was a considerably reduced number of cells expressing SCHAD, which 
confirms the data from the western blots presented in Figure 5.4. Transfection with empty 
vector yielded no green signal (not shown).  
 
Figure 5.7 shows confocal images at higher magnification. When positive cells (green) for each 
variant were inspected, no differences could be seen as compared with cells transfected with 





Figure 5.6 - Immuno-staining of the four SCHAD-V5 variants evaluated by fluorescence microscopy. HEK293 SCHAD 
KO cells were transiently transfected with the SCHAD-V5 WT, G34R, K136E, I184F and M188V plasmids. Cells were 
immunostained 48 hours post transfection. Fluorescence microscope images taken with a 20x objective (= 200x magnification). 




Figure 5.7 – Immuno-staining of the four SCHAD-V5 variants and of mitochondria evaluated by confocal microscopy. 
HEK293 SCHAD KO cells were transiently transfected with the SCHAD-V5 WT, G34R, K136E, I184F and M188V plasmids. 
Transfection with pcDNA3.1 was included as a negative control. Cells were immunostained 48 hours post transfection. 
Confocal images were taken with 63x objective plus 4x zoom. DAPI = blue. Mito Tracker = red. Primary antibody = anti-V5. 





5.2.4 Protein stability of SCHAD-V5 variants  
The data obtained so far strongly suggested that protein stability was reduced for two of the 
pathogenic SCHAD variants (G34R and I184F). To investigate whether protein instability 
could be a common feature of rare SCHAD variants, a set of cycloheximide chase assays were 
conducted. Cycloheximide is an agent that inhibits protein synthesis. We did not include the 
variants G34R and I184F as they were undetectable on western blots (see Figure 5.4). Instead, 
we analysed the remaining two variants (K136E, M188V) together with 11 other rare SCHAD 
variant constructs previously made by the group (Kelly Velasco, unpublished). HEK293 
SCHAD KO cells were transiently transfected with SCHAD-V5 constructs as before. Forty-
eight hours after transfection the cell medium was removed and fresh medium containing 
cycloheximide was added to the cells. Cells were then harvested at four different time points: 0 
h, 2 h, 8 h and 24 h after cycloheximide addition. Protein concentration of the cell lysates were 







Figure 5.8 – Assessment of SCHAD-V5 variant protein stability by cycloheximide chase assay. HEK293 SCHAD KO 
cells were transfected with SCHAD-V5 WT and 13 rare SCHAD variants. Cells were treated with cycloheximide 48 hours post 
transfection and harvested at four different time points: 0 h, 2 h, 8 h and 24 h. SCHAD-V5 (37 kDa) was detected by anti-V5. 
Tubulin (50 kDa) was used as a loading control. For WT, H170R and G303S, representative images from two experiments are 






The amount of each SCHAD-V5 variant detected was quantified and normalized by dividing 
the signal of the SCHAD-V5 band by the signal of the corresponding tubulin band. This was 
done to compensate for potential differences in the loading of the gel and in the transfer to the 
membrane. P258L was almost fully degraded already at the 0 h time point, and at the 24 h time 
point no protein could be detected. A gradual degradation of SCHAD (normalized to tubulin) 
could be detected for three of the variants: I33M, H170R and G303S (Figure 5.9). There was 




Figure 5.9 – Quantification of results from cycloheximide chase assay. A gradual decrease of the SCHAD-V5 levels 
(normalized to tubulin) could be detected for I33M, H170R and G303S. The protein levels at each time point are shown relative 


































5.3 Interaction of the SCHAD-V5 variants with the GDH protein 
A previous study suggested that SCHAD serves as an inhibitor of the enzyme glutamate 
dehydrogenase (GDH) [38]. We therefore decided to test the interaction between this protein 
and the different SCHAD variants by co-immunoprecipitation (Co-IP). HEK293 SCHAD KO 
cells were co-transfected with a plasmid expressing the human GDH protein and the various 
SCHAD-V5 plasmids. In addition to the two pathogenic variants K136E and M188V that were 
stable enough to be detected on western blots (Figure 5.4), we included seven of the other rare 
variants available in the group. V5-antibody was covalently coupled to an amine-reactive resin 
packed in a column, and 48 hours after transfection the cellular lysate was run on the column 
to capture the V5-tagged protein. If GDH (target protein, “prey”) interacted with the V5-tagged 
SCHAD variant (“bait” protein, captured on the column), it would be indirectly captured. The 
interaction complexes were eluted and analysed by SDS-PAGE and western blotting. 
 
Before starting the set of experiments, the procedure described by the manufacturer of the Co-
IP kit was optimized using cell lysates containing WT SCHAD-V5 to determine the minimum 
amount of washes needed to get rid of all unbound proteins of the cellular lysates. The third and 
fourth wash after incubation of the cell lysate in the column were collected and analysed by 
SDS-PAGE (Figure 5.10A). While there were still several protein bands visible after three 
washes, no bands appeared after four. It was therefore decided to use four washing steps. An 
additional washing step with conditioning buffer (wash X) suggested by the manufacturer was 
also tested to see if this could improve the results. No differences were observed and therefore 
this step was not included in the optimized protocol.   
 
Since the V5-antibody is covalently coupled to the resin, the Co-IP columns could be reused. It 
was therefore important to find the required number of elutions at the end of the experiment to 
completely clean the column before starting a new round of Co-IP. Elution number four and 
five were collected for comparison (Figure 5.10B). No improvements were observed after the 




Figure 5.10 – Optimization of Co-IP protocol. A) Samples from the third and fourth wash steps were collected and analysed 
by SDS-PAGE and Coomassie staining. Note remaining weak protein bands after the third washing step (arrows). Wash number 
four was also compared to a sample from an additional washing step (X) with conditioning buffer. B) Optimization of number 
of elution steps. Elution number four and five were collected for comparison.  
 
 
Altogether, GDH binding was tested by Co-IP for nine SCHAD variants and the WT protein. 
The results are shown in Figure 5.11. As seen in the top row, the SCHAD WT protein did 
capture GDH. A weak protein band in the anti-GDH IP eluate could also be detected for five of 
the other variants (F92C, Q152H, G205A, P215T, R221H). This suggested that the remaining 
variants bound GDH more weakly or not at all. However, protein bands were detected in the 
negative control lanes for some variants (F92C, K136E, M188V, P215T), which decreases the 




Figure 5.11 – Co-IP of GDH with SCHAD-V5.  I = Input cell lysate,  IP = elution from the V5-column, – = elution from the 
negative control column that had no V5-antibody. SCHAD (37 kD) was detected with anti-V5 and GDH (50 kD) with anti-






5.4 Purification of the four SCHAD variants after bacterial expression 
pET-MBP-SCHAD plasmids expressing the four variants were transformed into BL-21 E. coli 
cells and grown in culture. Protein expression was induced by adding IPTG to the growth 
medium. Pellet and supernatant samples from bacteria lysates were analysed by SDS-PAGE 
and Coomassie staining to examine whether the MBP-SCHAD protein was expressed and 
soluble (Figure 5.12). MBP-SCHAD had an expected size of 77 kDa (predicted using the 
ExPASY “Compute pI/Mw tool” https://web.expasy.org/compute_pi/), and it was known from 
previous experiments that protein expressed from the WT construct appears as a prominent 
band at approximately 75 kDa. All variants were successfully expressed and the majority of the 
protein was found to be soluble. A minor amount of protein was found in the pellet fraction. It 
looked like expression of G34R and K136E either resulted in more protein or these protein 
variants were more soluble than the two others. M188V had less protein in the pellet fraction, 




Figure 5.12 – Bacterial expression and solubility of the MBP-SCHAD variants. The pET-MBP-SCHAD variants G34R, 
K136E, I184F and M188V were transformed into competent E. coli bacteria cells. Cells were grown in LB medium with 
glucose, and protein expression was induced with IPTG overnight. Pelleted bacteria were suspended in PBS and sonicated. 
After centrifugation, samples from supernatants and pellets resuspended in equivalent volumes were analysed by SDS-PAGE 







The MBP-SCHAD variants, which also had a His-tag, were then purified from the harvested 
bacterial pellets from 200 ml cultures by immobilized metal affinity chromatography (IMAC, 
Ni-Sepharose matrix), followed by gel filtration at the Department of Biological Sciences, 
University of Bergen by Kelly Velasco. Figure 5.13 compares the resulting IMAC 
chromatograms for the different SCHAD variants. The grey line shows the elution buffer 
gradient. K136E and M188V eluted later compared to the WT, which could indicate a tighter 
binding of these variants to the Ni-Sepharose matrix. The eluted fractions containing protein, 
in addition to samples from supernatant, pellet and flow-through from the harvested pellet, were 
analysed by SDS-PAGE for verification as shown in Figure 5.14. MBP-SCHAD could be 





Figure 5.13 – Chromatograms from IMAC purification of the MBP-SCHAD-His WT and variants G34R, K136E, I184F 






















Figure 5.14 - Sampled fractions from IMAC of His-MBP-SCHAD WT and variants G34R, K136E, I184F and M188V. 
The samples were analysed by SDS-PAGE and Coomassie staining. SN = supernatant, FT = flow through, P = pellet. Numbers 
on top of the gel correspond to the various fractions tested. A) MBP-SCHAD WT. Arrow points to the SCHAD band. Image 
provided by Kelly Velasco). B) MBP-SCHAD G34R. C) MBP-SCHAD K136E. D) MBP-SCHAD I184F. D) MBP-SCHAD 





However, after the IMAC step MBP-SCHAD was not considered sufficiently pure as judged 
from the gels (Figure 5.14). Therefore, a second purification step was needed. Fractions with 
the expected MW band after IMAC were pooled and purified by size exclusion chromatography 
(SEC, HiLoad 16/600 Superdex 200 column, performed by Kelly Velasco). From previous 
experiments performed in the group, it was known that dimerized MBP-SCHAD eluted in gel 
filtration fractions C10-D2 (Figure 5.15A). The gel filtration chromatograms are included in 
the Appendix (Figure A.1). The fractions collected for the four variants were then analysed by 
SDS-PAGE (Figure 5.15B-E). For G34R, a weak MBP-SCHAD band could be detected in the 
C1 fraction (Figure 5.15B), but this sample belonged to a volume eluted before the previously 
observed volume for the MBP-SCHAD dimers (Figure A.1) and most likely contained larger 
MBP-SCHAD oligomers. The amount of SCHAD in the correct fractions, as exemplified by 
the D10 and 11 lanes, was considered too low to continue with any experiments. For I184F 
(Figure 5.15D), MBP-SCHAD could be detected in all analysed fractions, but in a very low 
amount. For the two variants K136E (Figure 5.15C) and M188V (Figure 5.15E), SEC 
purification was successful. As seen from the SDS-PAGE there was a strong bad of the expected 
MW in the expected range for both variants and the amount was considered sufficient for further 







Figure 5.15 – Sampled fractions from of MBP-SCHAD-His WT and variants G34R, I184F and M188V after gel 
filtrations. Samples were analysed by SDS-PAGE and Coomassie staining. Numbers on top of the gel correspond to the various 
fractions tested. A) MBP-SCHAD WT (Image provided by Kelly Velasco). Note arrow pointing to the high MW band.                 
B) MBP-SCHAD G34R. C) MBP-SCHAD K136E. D) MBP-SCHAD I184F. E) MBP-SCHAD M188V.  
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5.5 Enzymatic activity of MBP-SCHAD variants  
The purified proteins were used to measure the enzymatic activity of the variants in comparison 
to the activity of WT SCHAD. The gel filtration fractions with highest concentration and purity 
were pooled and concentrated, and protein concentration was measured by a NanoDrop 
spectrophotometer. Each variant (0.5 μg and 1.0 μg) was analysed by SDS-PAGE adjacent to a 
WT standard ranging from 0.1-0.7 μg (Figure 5.16). The intensity of the bands could thereby 
be quantified compared to WT bands to account for potential impurities in the samples. After 
correction, the concentration of K136E (Figure 5.16A) and M188V (Figure 5.16C) was 
estimated to 0.22 μg/μl and 0.43 μg/μl, respectively. An additional observation for the K136E 
variant was that it degraded when stored at 4˚C over a period of 3-4 days (Figure 5.16B). This 
was not the case for WT MBP-SCHAD.  
As very small amounts of I184F could be detected by SDS-PAGE (Figure 5.15D), one attempt 
was made to concentrate all D-fractions from the gel filtration. The concentrated sample got a 
final concentration under the detection limit of the NanoDrop spectrophotometer. When 
running the sample by SDS-PAGE, the sample appeared degraded and the protein was therefore 




Figure 5.16 – Quantification of purified and concentrated MBP-SCHAD variants prior to the enzymatic assay.                 
A) Quantification of the K136E variant. The concentrated sample (0.5 and 1.0 μg) from SEC fractions D12-D7 was run adjacent 
to a WT standard with protein concentrations ranging from 0.1 to 0.7 μg. B) After 3-4 days at 4˚C the MBP-SCHAD K136E 
was degraded. Note reduced amount of 75 kDa for K136E compared to the gel on the left and new bands at lower MW. C) 
Quantification of M188V protein concentration. Concentrated sample (0.5 and 1.0 μg) from SEC fractions D12-D6 run adjacent 





Since G34R and I184F could not be purified, only K136E and M188V were tested in the 
enzymatic assay. The measurements were done at saturated conditions of the substrate acetyl-
CoA and the cofactor NADH. The results are shown in Figure 5.17. Two replicates were done 
for M188V and one for K136E and the WT, each one with three measurements. The enzymatic 
activity of K136E and M188V MBP-SCHAD was 89 μmol/min/mg and 66 μmol/min/mg 
respectively, whereas the WT protein had an activity of 705 μmol/min/mg. This shows that the 
two SCHAD variants have a severely reduced enzymatic activity.   
 
 
Figure 5.17 – Enzymatic activity assay for MBP-SCHAD WT and the variants K136E and MI88V. The assay was 
performed with 0.07 μg enzyme and substrate and co-factor saturation conditions at 37 ̊ C. Two replicates were done for M188V 
and one for K136E and the WT, each with three measurements. The absorbance was measured at 340 nm every 30 sec for 5 
min. Measured absorbance was then plotted again time. The activity in µmol/min/mg was calculated from the slope of the 
straight part of the curve (before the reaction reached equilibrium), using a molar extinction coefficient for NADH of 6.3       


































5.6 Pathogenicity classification of SCHAD variants  
Finally, a reclassification was performed for the complete set of 16 rare SCHAD variants that 
are the focus of the group. The classification scale goes from 1, which is a benign variant, to 5, 
which is a pathogenic variant. The classification was done based on information about  known 
cases from published papers, frequency data of the variants in populations, functional studies, 
assessment of where the mutation is located in the protein (e.g. the mutated amino acid is highly 
conserved and in a region important for function), and so on. For support in the classification, 
the software package Alamut was employed. This is a program that contains relevant 
information from different public databases in addition to several bioinformatics prediction 
tools of how protein function is altered. In the reclassification (Table 5.1), information about 
the functional impact of the variants, obtained by the work of this thesis, was included.  
 
Table 5.1 – Classification of the degree of pathogenicity for SCHAD variants. Variants are interpreted by standards and 
guidelines from The American College of Medical Genetics and Genomics and the Association for Molecular Pathology.              
1 = pathogenic, 2 = likely pathogenic, 3 = uncertain significance, 4 = likely benign and 5 = benign.  * not published.  
Protein 
AA 




I33M C99G ExAC 1 NAD-binding 0.000470 3 
G34R G100C [30] 1 NAD-binding 0.000010 5 
D57E C171A [56] 2 NAD-binding 0.000017 4 
P86L C257T ExAC 2 NAD-binding 0.085000 1 
F92C T275G ExAC 3 NAD-binding 0.005321 3 
K136E A406G [69] 3 NAD-binding - 4 
Q152H G456T ExAC 4 NAD-binding 0.002026 3 
H170R A509G Irish patient* 4 NAD-binding - 5 
I184F A550T [16] 5 NAD-binding - 5 
M188V A562G [45] 5 NAD-binding - 4 
G205A G614C ExAC 5 NAD-binding 0.000280 3 
P215T C643A ExAC 6 Linker region 0.001674 3 
R221H G662A ExAC 6 Dimerization 0.001056 3 
P258L C773T [31] 7 Dimerization - 5 
N294S A881G ExAC 8 Dimerization 0.002216 3 





Recessive HADH mutations are a rare but important cause of CHI. Since SCHAD deficiency 
was established as a cause of CHI [33, 38], it has been an aim of our research group to fully 
understand the molecular basis of the phenotypic effect. In a previous study, 12 rare SCHAD 
variants have been functionally characterized (Kelly Velasco, unpublished data). Eight of these 
variants were chosen from the ExAC database. The chosen variants were rare point mutations 
present in human populations that resulted in amino acid substitutions and that were distributed 
throughout the protein. The remaining four variants were chosen from case reports of patients 
with CHI due to HADH mutations. During the initial study, it was realised that addition of more 
variants reported as pathogenic would strengthen the overall data. Thus, the rationale behind 
the current thesis was to complement the ongoing project on SCHAD biology by including four 
new variants found in CHI patients. After searching through the literature, the following 
variants were identified in recent publications: G34R, K136E, I184F and M188V.  
 
In the present study, we examined the effect of these four new missense mutations with regard 
to protein expression, subcellular localization and enzymatic activity. We also expanded the 
earlier studies by investigating the protein stability and GDH interaction, which had not been 
studied for any of the variants. Thus, in some of our experiments we included all SCHAD 
variants1 available in the lab, 16 in total.  
 
6.1 About the newly selected SCHAD variants  
The four new variants were all chosen from case reports of CHI patients. The G34R variant was 
reported by Snider et al. in 2013, and found in a patient responsive to diazoxide [30]. No other 
information was available about this patient. K136E was identified in a patient from Turkey by 
Flanagan et al. in 2011. The patient was diazoxide-responsive and had normal levels of 
acylcarnitines and urinary organic acids [69]. I184F was identified in two Indian sisters by 
Satapathy et al. in 2016. The sisters had recurrent episodes of seizures and hypoglycaemia, 
hyperinsulinemia and mild hyperammonemia [16]. M188V was identified in a patient from 
Bangladesh by Kapoor et al. in 2009. No abnormal levels of acylcarnitines and urine organic 
acids were detected, but the patient had a significantly decreased SCHAD activity compared to 
controls. The patient was responsive to diazoxide, but was severely protein sensitive and 
                                                          
1 For simplicity, the full name of the expression vectors will not be used in the Discussion. SCHAD when expressed 
in HEK293 cells = SCHAD-V5-His. SCHAD when expressed in bacterial cells = His-MBP-SCHAD. 
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continued to have episodes of hypoglycaemia [45]. All the four variants were homozygous in 
the patients, and the clinical findings were consistent with the CHI phenotype caused by HADH 
mutations. There were therefore good reasons to consider the variants as being causative of the 
disease.   
 
6.2 Expression and subcellular localization of SCHAD variants in mammalian cells  
To complement the previous study done by the group, we investigated the effect of the new 
variants on protein expression and subcellular localization in HEK293 cells. When testing the 
protein expression of the SCHAD variants by western blot analysis, the two variants K136E 
and M188V were detected in similar amounts as the WT protein (Figure 5.4 A and B). For the 
two variants G34R and I184F, however, there was either no expression or expression levels 
were under the detection limit of the method. We also tested the expression of the four variants 
in a cell-free expression system. Here, all the variants were expressed in similar amounts as the 
WT (Figure 5.4 C). This discards any technical problem with the low-expressed plasmids, and 
points instead to degradation of these variants through a quality control system present only in 
cells. This was further supported by the results from RT-PCR (Figure 5.5), which showed 
similar levels of mRNA for all the variants. Even though this technique only gives an 
approximate estimation of the mRNA levels, these data suggest that the quality control event is 
most likely happening at the protein level, downstream of transcription. For a more precise 
quantification, quantitative real time PCR (qPCR) could have been used.  
 
In agreement with the western blot results, immunostaining of transfected HEK293 cells 
showed lower fluorescent levels, though not fully absent, of the SCHAD variants G34R and 
I184F when compared to K136E, M188V and the WT protein (Figure 5.6). At low 
magnification levels it seemed like there were only a few cells expressing  G34R and I184F, 
but a closer inspection revealed that many cells had very low expression levels (detectable at 
high magnifications), while very few cells had similar expression levels as the cells transfected 
with the WT constructs. Thus, in a few cells, these variants were apparently able to escape 
quality control. One hypothesis is that the positive cells are in a stage of the cell cycle where 
protein degradation pathways are less active or down-regulated. This is, however, only a 
speculation and further experiments will be needed to find the explanation. Notably, for all 
variants the protein was expressed in the expected subcellular localization, i.e. in the 
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mitochondria (Figure 5.7). This is not surprising, since none of the variants affect the N-
terminal signal peptide sequence that directs the protein to the mitochondria.  
 
Very few studies have tested the level of expressed SCHAD missense variants in cells from 
patients. Two of the variants that have been investigated in this regard are P258L (Clayton et 
al. 2001) and G303S (Vilarinho et al. 2012). Western blot analysis of patient fibroblasts 
revealed slightly decreased expression of P258L [62], whereas G303S had undetectable levels 
of expression [31]. In accordance with this data, work done in our group (Kelly Velasco, 
unpublished data) showed reduced protein expression of these variants in HEK293 cells, and 
overall very similar results to what described in this thesis for the G34R and I184F variants. 
G303S was also included in the RT PCR as shown in Figure 5.5. Since our test systems worked 
well for P258L and G303S, we consider it likely that the CHI patients carrying the G34R and 
I184F variants have reduced SCHAD protein levels. Likewise and interestingly, the patients 
carrying the K136E and M188V variants may have normal SCHAD levels, indicating that a 
deficiency of the protein cannot explain the disease.  
 
All in all, protein degradation leading to too low SCHAD levels are likely to cause the disease 
in some cases of CHI due to HADH mutations. In accordance with this assumption, several of 
the mutations identified in patients are frame shifts or disrupt splice sites, which will lead to a 
truncated and/or missing SCHAD protein [34]. For other mutations, such as K136E and 
M188V, this is apparently not the case. Most likely, there are other defects in these variants that 
make them pathogenic. 
 
6.3 Stability of SCHAD variants in mammalian cells  
To further evaluate protein stability of the other available SCHAD variants, a cycloheximide 
chase assay was performed in transiently transfected HEK293 SCHAD KO cells. The SCHAD 
WT protein is very stable, and the intensity of its signal did not seem to decrease up to the last 
time point measured (24 hours) after treatment with cycloheximide. Among the SCHAD 
variants tested, I33M, H170R, P258L and G303S showed decreasing levels when normalized 
against a tubulin control (Figure 5.9). 
 
We conducted the assay only once, and many technical challenges appeared during blotting and 
quantification. As illustrated by the WT, the protein level was not completely stable from 0 h 
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to 24 h (Figure 5.9), and it actually looked like it increased at the 2 h and 8 h point. Several of 
the other variants (e.g. D57E, P86L, K136E) also gave inconsistent results, e.g. the signal 
appears stronger with time or it fluctuated. The reasons for this can range from differences in 
transfection efficiency and cell viability, to lack of uniformity during detection. The 
normalization performed with the quantification of the western blot signal solves technical 
problems regarding protein concentration measurements and gel loading. It would also account 
for detection problems as long as the loading control has the same defect as its corresponding 
SCHAD band. This worked well for the P215T variant, which looked unstable at first glance 
(Figure 5.8), but after the quantification and normalization there was no decrease over time. 
Replicates of the cycloheximide experiment should decrease the effect of the potential errors 
on the final results, and will allow us to perform a statistical analysis. 
 
The loading control tubulin was very weak in several of the blots, which made quantification 
difficult. Nevertheless, the variant G303S showed a very clear gradual protein degradation with 
a constant tubulin control. This was also the case for P258L, which was detected in very low 
amounts already at the 0 h time point. We are therefore confident that results from these two 
variants are reliable. As mentioned in Chapter 6.2, the variants G303S and P258L are 
pathogenic and already known to be unstable in patient samples. Degradation of the H170R 
variant was not obvious when looking at the blot, but after relative quantification against the 
tubulin control (which increased in intensity), it showed a gradual degradation similar to that 
of G303S. Notably, H170R is classified as pathogenic. The I33M variant had a less conspicuous 
rate of degradation than the aforementioned variants, but was still less stable than WT SCHAD. 
When purified from E. coli cultures, this variant degraded faster than the WT at 4°C (Kelly 
Velasco, unpublished), which further supports that I33M is unstable.   
 
The cycloheximide assay might benefit from sampling at longer time points. As noted, the 
SCHAD protein is very stable, and it could be that the instability of some variants is only 
perceived at long term. After protein purification from E.coli the K136E variant was degraded 
after a couple of days storage at 4˚C (Figure 5.16B). This could indicate that the K136E protein 
is more unstable than the WT SCHAD, even though there was no obvious difference detected 




6.4 The effect of SCHAD variants on GDH interaction 
It has been shown that SCHAD interacts with the enzyme GDH, and it is thought that SCHAD 
deficiency leads to CHI through the loss of the SCHAD inhibitory effect on GDH [38, 42]. This 
has been demonstrated by extensive analysis in Hadh knock out mice [38]. The aim of the Co-
IP was to test whether we could replicate the in vitro interaction between the SCHAD WT 
protein and GDH, and investigate if the SCHAD variants had altered capacity to bind GDH. As 
shown in Figure 5.11, after immunoprecipitation of SCHAD WT, a GDH band appeared in the 
western blot, which confirmed a physical interaction between these two proteins. We therefore 
managed to reproduce what has been reported in literature [38, 42].  
 
However, this assay proved technically challenging and the overall results were difficult to 
interpret and draw conclusions from. The most convincing results come from variants that show 
similar GDH binding compared to the WT. These are Q152H and G205A, which are variants 
with unknown significance. For the variants F92C and P215T there was bait protein (SCHAD) 
detected in the Co-IP column, but also in the negative control column. The negative controls, 
though, showed a positive signal that was less strong than the IP signals. Protein detection in 
the negative control experiment is likely to be caused by nonspecific binding of the protein to 
the coupling resin. For the pathogenic variants K136E and M188V, and the I33M and N294S 
variants with uncertain significance, there was no interacting GDH protein detected. Attempts 
were made to overexpress the signals of the blot, but still no bands were visible. This could 
either result from weak protein:protein interactions that cannot withstand the washing protocol, 
or a missing ability to interact. The results indicate that these variants bind GDH less well than 
the WT, but we cannot be certain since the inputs of SCHAD protein had lower signal, and the 
negative output therefore may be due to detection limitations.  
 
After the assay had been performed, we realised that the low expression levels of the R22IH 
variant were not as expected as this variant had been stable during earlier tests. Control 
sequencing showed that the R221H construct had an extra mutation (p.E118Q) introduced 
during the in vitro mutagenesis procedure. The data for R22IH therefore have to be discarded 
and the experiment repeated with the correct construct.  
  
Even though the same procedure was followed for each variant, there are several limitations in 
providing exactly the same conditions for each experiment, which is needed for reliable 
comparison. First, there might be seeding and transfection differences. Second, the columns 
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might not be exactly similar as each one is prepared separately in the lab. This could explain 
the problems with the negative controls and of uniform binding. Third, all variants cannot be 
blotted onto the same membrane and this could give rise to detection differences, decreasing 
the comparability between experiments. The first problem could be approached by using 
quantifiable amounts of purified protein, knowing then that the input is the same for all 
experiments. The second problem could be approached by preparing new columns in parallel 
for each Co-IP instead of reusing them. The third problem could be approached by always 
loading each variant next to the WT experiment, but this would increase the amount of work 
and materials used considerably.  
 
6.5 Protein purification of SCHAD variants expressed in bacteria  
In addition to expressing the new variants in the mammalian cell line HEK293, we also mutated 
the variants in a bacterial expression vector with an MBP tag (which makes the protein more 
soluble), transformed them into E.coli cells, and induced protein expression. Bacterial systems 
allow higher expression levels of the desired protein, in combination with lower endogenous 
expression of other proteins. The proteins were purified from the bacteria by IMAC and SEC. 
This experimental work was done in cooperation with Kelly Velasco, who handled the 
purification columns.  
 
SDS-PAGE analysis of samples taken from the pellet and supernatant after lysis of the bacteria 
showed that for all variants there were significant amounts of the recombinant protein in the 
pellet fraction (Figure 5.12 and 5.14). This indicates the presence of insoluble protein. 
Analysing the flow-through samples from the IMAC step likewise, the M188V variant appeared 
to have less protein in the flow-through, which indicates a stronger binding to the column. 
However, we have to do more replicates to see if these trends are consistent, or if the differences 
are due to technical issues (bacteria handling, expression, gel loading, buffer composition, etc). 
 
As seen in Figure 5.13, the IMAC column captured less G34R and I184F. The variants also 
eluted at different volumes. When gradually increasing the percentage of elution buffer added 
to the column, molecules that are weakly bound will be eluted first. The tendency was that 
K136E and M188V bound stronger to the matrix of the column, but we do not know how 
reproducible this is. The stronger binding of M188V corresponded to the low amount of protein 
in the flow-through sample for this variant, as mentioned above. The fractions containing the 
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SCHAD protein nevertheless still contained many contaminants (Figure 5.14) and further 
processing by SEC was therefore needed. 
  
During SEC, large proteins elute first, while the small proteins are retained in the pores of the 
matrix and hence elute at a later volume. SCHAD WT had previously been purified several 
times (by Kelly Velasco), and it was already known that the protein dimer (154 kDa) should be 
eluted at approximately 70 ml. Even though the G34R and I184F SCHAD variants were 
detectable after affinity chromatography, the recovery of protein after SEC was very low. We 
do not know the reason, but some suggestions are: 1) The protein variants degrade fast and are 
so unstable that they are lost during processing. 2) The proteins are aggregating to such an 
extent that they are eluted from the column before they show up in the chromatogram. 3) The 
amount of material that we are left with after IMAC is already very low, and with the material 
lost during the processing stage, variants become so diluted that they cannot be detected. The 
purification worked well for K136E and M188V, but the recovery of purified protein was lower 
than for the WT (Figure A.1). 
 
As seen in Figure 5.15A, the fractions containing the SCHAD dimers (C10-D2 fractions) also 
contained a band of higher molecular weight. This band probably contains other protein 
monomers with similar shape/volume as the SCHAD dimer. As these molecules fit in the same 
pores in the matrix, they cannot be separated from MBP-SCHAD by SEC.  
 
6.6 Enzymatic activity of the SCHAD variants  
Even though all four variants that were the focus of this thesis are reported as pathogenic, two 
of them (K136E and I184F) were expressed in similar amounts as the WT and appeared to be 
stable in mammalian cells. As a part of the characterization of these variants, we therefore 
decided to measure their enzymatic activity, comparing it with that of the WT protein. When 
measuring the enzymatic activity of SCHAD K136E and M188V it was found that both variants 
exhibited enzymatic activity, but considerably decreased compared to the WT protein (Figure 
5.17). The decreased activity of M188V is in agreement with the SCHAD activity found in the 
patient reported by Kapoor et al. [45]. For the K136E variant there was no reported 
measurement of SCHAD activity [69], but both patients had normal levels of acylcarnitines and 
urine organic acids which indicates that there is some residual SCHAD activity. The patients 
with K136E and M188V mutations therefore illustrate the importance of considering SCHAD 
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deficiency as the cause of CHI even when no abnormalities can be detected in acylcarnitines 
and urine organic acids. 
 
6.7 Formal classification of the degree of pathogenicity of rare SCHAD variants 
During genetic screening of patients with inherited disorders, an increasing number of new 
variants of disease-causing genes are now being discovered. This is particularly true for high-
throughput methods like whole-exome and -genome sequencing. The number of variants with 
uncertain functional significance causes problems during diagnostics of patients, and hence it 
is important to understand the clinical significance of a given variant. The data gathered in this 
study was combined with information from literature and bioinformatics tools to reclassify the 
total set of SCHAD variants that the group is working on. Eight of 16 variants were classified 
as either likely pathogenic or pathogenic, while one was classified as benign (Table 5.1). Seven 
of the variants were classified as of uncertain significance, as no conclusions could be drawn 
about their impact on SCHAD function and CHI. To be able to reach a conclusion for these 
variants, further studies, and preferentially with additional methods, are needed. Here, the 
process of classification will be explained for three of the variants: one classified as benign, one 
of uncertain significance, and one classified as pathogenic.  
 
G34R, located in the NAD+-binding domain, was reported as pathogenic by Snider et al. in 
2013. [30] According to Barycki et al. 1999, the G34 residue plays an important role in the 
binding of cofactors to SCHAD. The NAD+-binding site is located at the consensus nucleotide-
binding motif comprised of the residues G34-G35-G36-L37-M38-G39, and is adjacent to the 
active site H170 which has an essential function in the catalytic mechanism [35]. The G34R 
mutation is predicted to be disease-causing by MutationTaster and probably damaging by 
PolyPhen-2. The G34 amino acid is highly conserved from C. elegans and there are moderate 
physiochemical differences between glycine and arginine. Our assays have shown that there are 
reduced protein levels of this variant after expression in HEK293 cells, likely due to a protein 
quality control mechanism. The G34R mutation is therefore classified as pathogenic.  
 
Studies performed on the variant I33M in this thesis, in addition to an earlier unpublished study 
by the group, have indicated that there are some abnormalities regarding protein stability. The 
protein appeared to be somewhat unstable during protein purification and in the cycloheximide 
assay, and the Co-IP assay indicated an interrupted interaction with GDH. However, I33M has 
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not been previously reported as pathogenic. When analysing this variant in Alamut, the in vitro 
tools MutationTaster and Polyphen-2 predicted the variant to be disease causing and possibly 
damaging, respectively. The I33M amino acid is moderately conserved, and there is a small 
physiochemical difference between isoleucine and methionine (Grantham distance 10). 
However, our experiments are not considered sufficient to classify I33M as pathogenic, and it 
is therefore classified as a class 3 mutation with uncertain significance until further evidence is 
collected.  
 
Polymorphisms are common variants with a minor allele frequency >1% in the population [51]. 
The P86L variant has a substantially higher frequency than the other variants selected for this 
study, and is the only common variant in the HADH gene that leads to a change in the amino 
acid composition of the protein [34]. P86L is also located in the NAD+-binding domain. Case-
control studies in the Netherlands and Denmark indicated that the minor allele frequency of 
SCHAD P86L varied between 6.6 and 9.2%. No significant differences in levels of circulating 
glucose, insulin and lipids, enzyme activity, or SCHAD protein and mRNA levels could be 
detected between carriers of the mutation and non-carriers. It was therefore concluded that the 
P86L variant had no effect on enzyme levels or function [70]. As CHI caused by SCHAD-
deficiency is a very rare disease, the allele frequency of this variant strongly indicate that this 
variant is benign. The variant was also predicted to be benign by the in silico tools of Alamut, 
and our assays show normal protein expression in mammalian cells and no abnormalities in 
















Pathogenic variants of the fatty acid oxidation enzyme SCHAD cause congenital 
hyperinsulinism of infancy (CHI). The overall aim of the study was to functionally characterize 
rare SCHAD variants, and to obtain a better understanding of how SCHAD affects insulin 
secretion.  
The findings described in this thesis suggest that the cause of pathogenicity for the two variants 
G34R and I184F are protein instability, resulting in SCHAD deficiency. The variants K136E 
and M188V appear stable, but have impaired enzymatic activity. It has previously been 
postulated that the main explanation of CHI caused my mutations in the HADH gene is the lack 
of SCHAD protein [38]. Our results indicate that some pathogenic SCHAD variants are 
expressed at normal protein levels, but with defects in their function. Significant changes in 
enzyme activity are an indicator that the overall protein structure has been perturbed and that 
the interaction with other proteins can be severely affected. We managed to replicate the 
reported interaction of SCHAD WT with GDH, while a missing interaction was observed for 
















8. Future perspectives  
 
To finalize and extend the work described in this thesis, the following studies should be carried 
out:  
 The cycloheximide and enzymatic assays need to be replicated. This will make it 
possible to perform statistical analysis, hopefully enabling conclusive results to be 
obtained for all variants.  
 Alternative methods to evaluate the protein interaction of SCHAD and GDH need 
to be found. Pull-down experiments with purified proteins is one such approach, 
which also will help to evaluate if the interaction is direct or not.  
 There is evidence that SCHAD is part of a large metabolic super complex of proteins 
[44]. It would therefore be very interesting to search for novel SCHAD interaction 
partners, for example by biochemical methods like yeast-two-hybrid screening or 
computational methods like network analysis.  
 The effect of the SCHAD variants on the enzymatic activity of GDH should be 
evaluated to see if there is a varying degree of inhibition. This may aid in the 
evaluation of which variants are pathogenic.  
 Expression of SCHAD variants were tested in HEK293 cells. A natural next step 
would be to evaluate the effects of SCHAD expression in a more relevant model, 
like directly in pancreatic beta cell lines. This would give a better indication of how 
the SCHAD variants directly affect insulin secretion. It wold also be interesting to 
investigate if rare SCHAD variants can be protective against diabetes later in life.  
 It would be interesting to go through new collections of human sequence data 
obtained by next generation sequencing, to identify novel SCHAD variants and to 
investigate if we can extract more information (new variants or medical data) about 
the role of SCHAD in insulin regulation using tools for functional characterization 
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Protein purification  
The frozen 200 ml bacterial pellet was resuspended in 20 ml lysis buffer with protease inhibitors 
without EDTA and divided in two aliquots. After 6 x 15 seconds of sonication, lysates were 
centrifuged at 15 000 g for 20 minutes at 4˚C.  Two μl of the supernatant and the re-suspended 
pellet in equal volume were saved for analysis by SDS-PAGE. The supernatant was then 
filtrated through a 0.45 μm filter unit, and loaded into a Ni Sepharose column (HiTrap Blue HP, 
5 ml) using an ÄKTAexplorer liquid chromatography system at a flow rate of 0.5 ml/min. The 
washing and elution were made at a flow rate of 1 ml/min. Bound protein was eluted from the 
column with an elution buffer gradient length of three column volumes (CV). Samples from the 
flow through (2 μl) and the fractions containing proteins (6 μl) were taken for later analyses by 
SDS-PAGE. Since the fractions containing the protein of interest had many other contaminant 
proteins, they were combined and further processed using a gel filtration column (HiLoad 
16/600 Superdex 200 g). A sample volume ranging from 0.5 to 2.5 ml was injected at a flow 
rate of 0.5 ml/min. The flow rate for the rest of the run was 1 ml/min. After 0.4 CV, 1 ml 




Figure A.1 – Gel filtration chromatograms from purification of MBP-SCHAD. Column: HiLoad 16/600 Superdex 200 g. 
mAu = milli absorbance units at 280 nm. The first peak (after 70 ml) corresponds to C10-D2 fractions in Figure 5.15A. The 
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